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Abstract 
 Synthetic cannabinoids, known as “spice” or “K2” among others, create an ever-changing 
challenge for the forensic chemist or toxicologist. The spectrum of compounds is constantly 
growing and evolving. Understanding the stability and degradation timelines for these under-
characterized substances will be valuable for forensic chemists across the globe as they endeavor 
to manage their case loads.   
 The focus of this study was to determine the stability of four specific synthetic 
cannabinoids, XLR-11, UR-144, AB-Pinaca, and AB-Fubinaca. The study used human blood 
spiked with the compounds of interest to mimic real forensic laboratory samples submitted for 
synthetic cannabinoid analysis. These whole blood samples were stored under three different 
temperature conditions, room or ambient temperature (22°C), refrigerator temperature (4°C), and 
freezer conditions (-20°C).  Scheduled testing on days 0, 3, 7, 14, 21, 28, 35, 42, 56, 70, and 84 
were spanned the study’s nearly three month duration, monitoring stability and degradation of 
the analytes spiked into whole blood samples. Whole blood samples were then extracted using a 
forward alkaline extraction at pH 10.2 and analyzed using a liquid chromatograph tandem mass 
spectrometer (LC-MS/MS). Results showed that AB-Fubinaca, AB-Pinaca, and UR-144 were 
relatively stable, while XLR-11 significantly degraded at ambient and refrigerated conditions. 
Frozen storage conditions were the only tested parameter able to preserve and stabilize all four 
compounds over the three month period. Therefore, it should be suggested that forensic blood 
evidence suspected of containing synthetic cannabinoid compounds should be stored in frozen 
conditions. 
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Introduction 
 Manufactured to mimic and/or exceed the pharmacological effects of 
tetrahydrocannabinol (THC) found in marijuana, synthetic cannabinoid compounds have 
hundreds of variants and isomers, and are in a constantly shifting market of compounds (Logan, 
2012). Twenty-one substances known as synthetic cannabinoids have been controlled by the 
Drug Enforcement Agency (DEA) under its Schedule I of the Controlled Substances Act as of 
2014. However, many more synthetic cannabinoids exist and are being sold under product names 
like “K2” or “Spice” (Logan, Reinhold, Xu, Diamond, 2012).  Easy accessed, these drugs in 
seemingly harmless packages are sold under euphemistic trade names such as “K2”, “Kush”, 
“Sexy Monkey”, “Black Diamond”, and “Dead Man Walking”. Most users are unconvinced or 
unconcerned about the potentially harmful side effects that can accompany smoking these 
deceptively-marketed compounds.   
 Synthetic cannabinoids have been designed to mimic the effects of marijuana by 
activating the body’s cannabinoid CB1 and CB2 receptors. However, these drugs have been 
discovered to have an even stronger binding potential to these receptors than does delta 9-
tetrahydrocannabinol, and thus a greater probability of toxic effects. The appeal of a quasi 
“legal” high and easy accessibility makes these drug compounds extremely popular with 
devotees (Harris and Brown, 2012). Such smoking mixtures can often be purchased at smoke or 
head shops, and also on the internet.  
 Since these drug compounds are becoming more popular, and controlled by the DEA as 
they are identified, the demand for their analysis in the forensic laboratory is increasing. In a 
survey conducted by The Center for Forensic Science Research and Education (2013), results 
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showed that practicing toxicologists believe that the full range of synthetic cannabinoids should 
be routinely pursued in applicable cases, demonstrating the general concern amongst forensic 
chemists and toxicologists that synthetic cannabinoids are of analytical concern.  While 
extraction methods have been established for specific synthetic cannabinoids, little has been 
done toward studying their stability, especially in whole blood. Ante-mortem forensic chemistry 
and toxicology laboratories often analyze biological fluids, such as serum and urine, but whole 
blood proves the most useful for true drug quantitation at the time of a crime or a death. 
However, in the forensic laboratory setting, the case may not be processed immediately after 
obtaining custody, especially in cases involving “driving under the influence” thus victimless 
crashes versus those involving a death. Therefore, sample holding-time in response to case 
prioritization backlog in the laboratory could negatively impact the concentration of synthetic 
cannabinoids in the sample or samples in question. 
 Assessment of the stability of these drug compounds in biological matrices is necessary 
for the forensic laboratory testing evidence specimens and for those collecting such evidence. 
Establishing more specific data about the most recently-detected synthetic cannabinoids can 
directly impact casework prioritization in forensic laboratories. Assessing a wide range of 
temperature conditions is also important spanning the range of conditions to which biological 
evidence may be subjected.  
Statement of the Problem 
 Establishing stability data for synthetic cannabinoids has numerous benefits for law 
enforcement and death investigation. In this study, not only are stability data being established 
for these commonly-encountered drugs of abuse, but a validated method for their quantitation in 
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whole blood is as well undertaken. Both of these pieces of information are vital to the forensic 
chemist or toxicologist who is currently working these types of cases in the laboratory. Stability 
of drugs in biological matrices is an analytical issue that has impacted forensic chemistry 
researchers. Simply put, drugs degrade. Whether related to shelf-life or in biological specimens, 
most if not all drugs or analytes of interest suffer from some type of degradation related to 
temperature conditions, storage container and preservatives, and specific biological matrices.  
 As a hypothetical illustration, take the example of a state trooper patrolling an interstate 
who notices an oncoming driver driving erratically. The driver is swerving in and out of lanes, 
thus endangering the other drivers. The highway patrolman stops the suspicious driver, 
suspecting that they are under the influence of alcohol and/or drugs. After failing a field sobriety 
test followed by a negative Breathalyzer assessment for alcohol, the suspect is taken in for an 
examination by a drug recognition expert, after which a blood draw is undertaken to assess illicit 
substances that may be present. It is then the obligation of that trooper, or officer, to turn the 
blood sample over to the proper authorities or forensic laboratory for testing. The interval 
between the blood draw and lodging, as well as the conditions experienced by the blood sample 
during this time, may be variable. The next hurdle to be overcome by the blood specimen is 
within the forensic examiner’s case load prioritization scheme. On a related front, what if the 
situation involves a discovered body, of which the time of death is uncertain? How might the 
time since death and ambient temperature have affected the blood and its contents? 
 The questions above are commonly asked in court by opposing counsel of law 
enforcement personnel having undertaken of these types of sample collections. However, similar 
questions can be asked of all forensic laboratories about specimen storage and testing conditions. 
It is customary for forensic laboratories to store biological specimens under refrigerated and 
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frozen conditions for preservation; but what about a specimen that is accidentally left out or in 
the mail at ambient temperature for a time?  These are all key quality assurance questions to be 
asked related to specimen degradation. Specimen and analyte degradation are a real concern in 
these scenarios.  
 Stability of analytes is a key factor in the processing of samples in the forensic 
laboratory. Drug compounds can be subject to degradation and instability from storage 
conditions, matrix effects, extraction methods, or instrumental conditions. Due to drug acidity or 
basicity, polarity, volatility, and chemical affinity, detection of drugs and other analytes of 
interest can be suppressed within a biological specimen, if not lost completely. This further 
demonstrates the importance of establishing a rigorous analysis protocol that produces reliable, 
reproducible results, and addresses specimen collection, transportation, and storage for the 
extraction, and instrument processing. Since synthetic cannabinoids are somewhat new on the 
drug market and their molecular structures are constantly evolving, little is known about their 
stability in biological specimens. Extraction methods have been used and validated by previous 
authors towards the specific cannabinoids of interest for this project (Shanks, Dahn, and Terrell, 
2012), but their specific stabilities have not been established.  
 It has been shown that some related cannabinoids of the JWH group, named for John W. 
Huffman, are relatively stable for 30 days under all conditions in human whole blood (Kacinko 
et al., 2011). But cases are not always assessed and analyzed in 30 days or less. If a substantial 
backlog exists for a forensic laboratory, it may take weeks if not possibly months for the case of 
interest to be analyzed and reported. Establishing a longer stability timeline provides more data 
as to how these synthetic cannabinoids may or may not possibly degrade based on their specific 
storage conditions. If substantial data and evidence of stability or degradation are established, a 
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predictive model may be projected to other cannabinoids of similar chemical structure or 
moieties.  
 Due to the lack of stability data for synthetic cannabinoids in blood in particular, there is 
a fundamental need to establish some sort of structural integrity timeline for these compounds. 
Their prevalence in the drug market is growing despite DEA Scheduling efforts, and if more 
information is not gathered about these compounds in a timely fashion, forensic laboratories will 
soon face additional difficulties.  
Background 
 Although research is limited as to degradation of the specific synthetic cannabinoids 
targeted in this study, some literature is available to assist in the analytical process, extraction 
techniques, and possible degradation timelines from previous structurally non-related stability 
studies. A short review of this relevant literature is provided as background to the present 
undertaking.  
 Synthetic cannabinoids are typically sold at head shops, smoke shops, and online across 
the United States and around the globe.  They are often marketed under trade names such as 
“incense”, “Spice”, or “K2” and all usually come with the warning, “Not for Human 
Consumption.” One of the first synthetic cannabinoids synthesized was JWH-018, also known as  
         
Figure 1. Molecular structures of JWH-018 and THC from Cayman Chemical (2014) 
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1-pentyl-3-(1-napthoyl) indole.  It was synthesized by the Huffman research group as a 
cannabinoid agonist, especially for the CB1 receptor in a fashion similar to tetrahydrocannabinol 
(THC), the pharmacologically active ingredient of marijuana.  The CB1 receptor is mainly 
expressed in the brain, and more importantly facilitates the central nervous system response to 
cannabinoid-like compounds (Ernst et al. 2012).  Synthetic cannabinoid compounds often exhibit 
a greater binding affinity and activation efficacy for the cannabinoid receptors compared to THC, 
which leads to significant side effects such as seizures, agitation, anxiety, tachycardia, 
hallucinations and psychotic episodes, or death. 
 After JWH-018 became a DEA Schedule I compound, other derivatives and moieties 
became available and were sold over-the counter (OTC), including: JWH-073, JWH-122, CP-47, 
and CP-497.  The structures of these compounds are provided below.  
             
Figure2.Molecular structures of JWH-073, JWH-122 and CP-47, 497 (left to right, respectively)  
Cayman Chemicals (2014) 
Ultimately, these derivatives would become controlled Schedule I substances, in the DEA’s 
efforts to control the growing synthetic cannabinoid market (Dunham et al., 2012). Current, 
casework observed at the Office of the Chief Medical Examiner of Oklahoma and trending 
literature suggests that AB-Pinaca, AB-Fubinaca, ADB-Pinaca, PB-22, UR-144 and XLR-11 are 
the predominant species encountered in drug evidence and in blood work. 
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Figure 3. AB-Fubinaca , AB-Pinaca, XLR-11, and UR-144 (left to right, respectively) Cayman Chem. (2014) 
 Shanks and Terrell (2012) have been successful at detecting synthetic cannabinoid 
compounds in blood.  In their work, detailed experimental conditions and extraction techniques 
for isolating JWH-018 and JWH-073 in post-mortem whole blood were documented.  Drug 
stability in postmortem matrices poses an added level of difficulty in detection and 
quantification, due to post-mortem byproducts produced in the autolysis and putrefaction 
processes of death.  Blood samples present a significant number of artifacts besides the drug or 
analyte of interest. For example, blood samples contain cholesterol as well as various proteins 
and metabolites that can alter the recovery of other analytes of interest. Dresen et al. (2010) 
validated a method for LC-MS/MS analysis of synthetic cannabinoids. Their study also 
incorporated stability studies, analyzing whole blood and serum in the assessment of freeze-thaw 
stability and long-term stability. They found that the stabilities of the analytes stored at room 
temperature in glass and polypropylene tubes were not dependent upon the material of the 
container.  For all of the tested compounds, refrigeration proved to be most effective storage 
conditions, compared to freeze-thaw cycle stability. Room temperature suffered a slight 
degradation after the 72-hour period. Shanks et al. (2012) validated their procedure for work on 
an Ultra Performance Liquid Chromatograph tandem Mass Spectrometer (UPLC-MS/MS), 
which is the instrumentation used in the current project. 
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 Kneisel and Auwater (2012) analyzed 30 synthetic cannabinoids in serum after liquid-
liquid extraction followed by LC-MS/MS analysis. Constructed similarly to Dresen et al. (2010), 
freeze and thaw stability and long-term stability (-20°C) was examined. Their study was 
configured as a stability study, using a specific time-schedule for analysis, individual 
temperature or environment conditions, and a spiked sample with the analytes of interest.    
 The stability of analytes of interest to forensic chemists and toxicologists in biological 
samples was addressed in a review published in the journal Analytical Bioanalytical Chemistry 
by Peter (2007).  Definitions and specific types of stability were consistent with those reported 
later in Clarke’s Analytical Forensic Toxicology (2013).  Peter (2007) found that stability must 
also be regarded as a process where the result depends on two pathways: degradation of the 
analyte and its potential in vitro formation from precursor and related compounds.  Another key 
aspect of stability studies is comparing the results of quality-control samples analyzed before and 
with the stability samples after being exposed to the conditions of interest.  
Stability studies begin with a designated set of concentrations in the test medium, 
whether blood or serum, so that a concentration calibration curve can be generated.  Then a 
blood or biological matrix sample will be spiked with the analytes of interest.  These known 
concentrations are then tracked according to a preset schedule with  the rate of analyte 
degradation being assessed.   
 As mentioned in the previous example, some synthetic cannabinoid compounds have 
been studied by forensic scientists during the development of extraction techniques and 
compound profiles while monitoring the evolving drug market. Some stability studies have been 
conducted to get an idea about how these compounds may degrade over time in evidentiary 
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samples, but no literature is available examining the stability of AB-Pinaca, AB-Fubinaca, XLR-
11, and UR-144, the most- recently observed and prevalent synthetic cannabinoids seen in 
casework for forensic laboratories at the present time (June 2014). Stability data for these 
compounds would be extremely useful to not only gain more insight into synthetic cannabinoid 
stability in biological matrices overall, but for the expected appearance of structurally related 
variants.  
Purpose of Study 
The goal of this study was to establish degradation data for four synthetic cannabinoid 
compounds, specifically AB-Pinaca, AB-Fubinaca, XLR-11, and UR-144, in whole blood.  
Variables such as time and temperature were explored for the conditions commonly encountered 
under which these samples are collected and stored before testing in forensic science 
laboratories.  In collaboration with the Office of the Chief Medical Examiner (OCME) 
Toxicology Laboratory, the impact of these variables in storage conditions were analyzed to 
generate chemical stability and degradation data for synthetic cannabinoids.  Due to the 
increasing popularity of these drugs and the growing inventory of compounds, an understanding 
of how these molecules degrade in biological matrices for interpretational purposes is vital 
information for forensic science laboratories, in particular as it relates to case prioritization 
schemes. The information was relevant for evidentiary purposes to know how long blood 
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Scope of Study 
 The scope of this study was bounded by the following areas: 
1. The purpose of this study was to establish stability and degradation for synthetic 
cannabinoids under a set of given storage conditions. Specific freeze-thaw stability was 
not determined, but instead correlated with data from ambient, refrigerated, and frozen 
temperatures.  
2. The study established degradation for four specific synthetic cannabinoids. While these 
are the most recent cannabinoids observed in casework, the scope of the study pertains 
only to the specific cannabinoids mentioned and cannot easily be applied to all synthetic 
cannabinoids.  
3. It was not the goal of this research to suggest that all or none of the synthetic 
cannabinoids suffer from degradation when left in appropriate storage conditions. 
Generalizations would not be appropriate to state affirmatively all or none suffer from 
stability issues. Further research will need to be conducted to apply findings to other 
certain synthetic cannabinoid compounds. However, this study may suggest initial 
parameters for study of related compounds, as well as, similar structural components 
following similar degradation profiles.  
Significance to the Field  
 Presently, there is no data published regarding the stability to the four specific synthetic 
cannabinoids being monitored in the study. This information, however, would be extremely 
useful to forensic chemists and toxicologists across the globe. Synthetic cannabinoids are an 
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international problem for law enforcement and for laboratory personnel. Knowing approximate 
drug stability before significant degraded loss occurred loss would be pertinent for all those 
involved in these cases. For instance, the earlier proposed DUI situation could quickly be 
handled and turned over to the proper lab personnel if law enforcement were aware of potential 
sample degradation. In return, forensic chemists and toxicologists would also know optimal 
possible storage conditions and time frame under which testing would need to be completed in 
order to achieve accurate and reliable results. The synthetic cannabinoid market is vast and 
quickly evolving. Trying to understand the stability of these species in biological matrices 
provides the best possible solution to maintaining evidentiary integrity, also making the 
difference between answering the cause of death question for a grieving family member when 
making a drug identification, or facing an “unknown” possible drug overdose cause of death 
certificate. Not only will the project provide a validated method for whole blood testing, but it 
will also gain insight into the stability of the four synthetic cannabinoids evaluated in the present 
study.   
Literature Review 
 The literature review will address the areas of related research that pertain to the analysis 
of degradation in synthetic cannabinoids in blood. The first section addresses the evolution of the 
synthetic cannabinoid market to gain a better understanding behind these compounds. The 
second brief section contains further information into the pharmacology of synthetic 
cannabinoids. The third section deals solely with the analysis types for synthetic cannabinoids 
for methodology practices. Finally, the last section highlights the impact of degradation studies 
in similar study areas and their typical study design. 
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History of Synthetic Cannabinoid Evolution 
Synthetic cannabinoids are typically sold at head shops and smoke shops across the 
country. They can be marketed as “Incense” or “Spice” and all usually come with the same 
warning, “Not for Human Consumption.” This label serves as a warning to deter unknowing 
users who are unfamiliar with the leafy material contained in the Mylar package, and to bypass 
requirements of the Controlled Substance Analogue Act enacted by the United States Congress 
in 1986. The seemingly harmless packages go by euphemistic names such as “K2, Mr. Nice Guy, 
Space, Barely Legal, Bombay Blue” and others. The packages contain a leafy plant material, 
sometimes fragrant, that is ostensibly sold for incense use, but instead is utilized as a smoking 
agent to reach a “legal” high. The sensation of an altered state of awareness is somewhat legal 
because the chemicals used to produce these are not all controlled by the DEA.  The popularity 
of these drugs expanded as availability increased and effects were noticed to be similar to 
marijuana (Logan et al., 2012).  However, the United States wasn’t the only country 
experiencing the growing popularity of these drugs.  Countries such as Germany, The 
Netherlands, Japan, and Russia have attracted the attention of enforcement agencies such as the 
UK Advisory Council on the Misuse of Drugs (ACMD) to study these major compounds to help 
classify the structures and hopefully control their distribution (Ernst et al., 2012).  The ACMD is 
a British public body that was established under the Misuse of Drugs Act of 1971 in the United 
Kingdom. It serves as a council to restrict availability of dangerous drugs, promotes research, 
and educates the public about the dangers of illicit drugs. 
 JWH-018 is one of the first and most infamous of the synthetic cannabinoid compounds. 
1-pentyl-3-(1-naphthoyl) indole, also known simply as JWH-018, was first synthesized by John 
W. Huffman. JWH-018 is a potent cannabinoid agonist, especially for the CB1 receptor in a 
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fashion similar to tetrahydrocannabinol (THC), the active ingredient of marijuana.  The CB1 
receptor is mainly expressed in the brain, and is more importantly in charge of the central 
nervous system response to synthetic cannabinoid compounds.  In March of 2010, JWH-018 
became a Schedule 1 controlled substance in the U.S., along with its other similar derivatives 
JWH-073, JWH-200, CP-47, and CP-497 (Dunham, Hooker, & Hyde, 2012).  
 
Figure 4. Molecular structures studied by Dunham. (2012) 
This ban halted the legal possession and consumption of these substances, but synthetic 
cannabinoids continued to be produced and synthesized as structural isomers and chemical 
analogs of Schedule 1 compounds.  
 The new isomeric compounds were given short names like JWH-018: JWH-412, JWH-
122, JWH-210, AM-2201, CP-47, 497.  Most of these compounds belong to the 
aminoalkylindole family, and express a similar binding affinity for the CB1 and CB2 receptors.  
JWH-018 has been a Schedule I controlled substance since March 1st, 2011. Many other 
compounds followed, being continually added to the DEA controlled substance list as they 
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appeared on the synthetic cannabinoid drug market.  However, as mentioned by Ernst et al. 
(2012), JWH-018 has reappeared on the market in Germany, and this is true for the United States 
as well.  The European market saw the appearance of a new compound, known as JWH-307, as 
well as the reappearance of JWH-018.  Since JWH-018 has become controlled, chemists and 
drug manufacturers in charge of making these substances started creating new isomers and 
compounds that produce the same or similar binding affinity for the CB1 receptor in the brain.  In 
Germany, JWH-307 was the new structurally similar compound introduced in 2012.  While it has 
been tested for its receptor binding affinities, not much spectroscopic information is known about 
this compound.   
             
 Figure 5. Molecular structures of JWH-307 and JWH-018 from Cayman Chemical (2014) 
For the European authorities, as well as worldwide, having little spectroscopic information  is a 
problem because JWH-307 is the first synthetic cannabinoid of the naphthoylpyrrole class, which 
means that the popular indole group that is typically used in synthetic cannabinoid compounds is 
substituted by a phenyl-pyrrole.  As demonstrated by JWH-307, synthesis of these compounds 
usually involves the movement or altering of functional groups on the naphthoylindole structure 
(Ernst et al. 2012).  
 Researchers in Germany discovered the napthoylindole alteration issue when they were 
introduced to a new product that was proving to be very dangerous to many teenage users having 
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purchased “Lava Red.”  In the study conducted by Ernst et al. (2011), JWH-122 was introduced 
as the new synthetic cannabinoid ingredient comprising the “Lava Red” product. 
 
Figure 6. Molecular structure of JWH-122 from Cayman Chemical (2014) 
This ingredient was shown to be (N-alkyl-3-(1-naphthoyl) indole, which was previously detected 
in only a few instances in Germany. Because JWH-122 was an emerging threat, the need to 
determine and characterize molecular structure, composition, and binding affinity became 
apparent.  Analyses were run for the “Lava Red” component, and in vitro experiments concluded 
that JWH-122 to be a very potent CB1 agonist with a low affinity constant, just like its 
predecessor JWH-018.  However, when compared to JWH-018, the Ki binding constant of JWH-
122 is lower by a factor of 10, therefore having a stronger binding affinity. Ki is an indication of 
how potent an inhibitor is; it is essentially the concentration required to produce half maximum 
inhibition.  Ernst et al. (2011) discussed how the development of JWH-122 and the lower 
binding affinity demonstrates the impact of JWH-018 becoming a controlled substance on the 
supply chain for drug analogs. Specifically, suppliers are finding other ways to create the same 
drug, with even stronger physiological effects.  This can lead to overdose cases as witnessed by 
German authorities with “Lava Red” (Ernst et al., 2011).  
Information about JWH substances can also be found in many locations online, often 
containing manufacturing information and reported personal mixtures that are dangerous to the 
user and the public.  JWH compounds, such as the aforementioned JWH-122 and JWH-307, are 
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only growing stronger in terms of CB binding abilities than the original JWH-018 substance, and 
are growing more popular with the increasing synthetic cannabinoid market worldwide.  These 
are two common JWH compounds found in “Spice” mixtures.  
In a publication by Gurney et al. (2014), synthetic cannabinoid compounds are suggested 
to have a life cycle of about 12-24 months after which they are replaced by the next compound in 
succession. In 2011, the DEA scheduled its first synthetic cannabinoids adding five compounds 
to Schedule I, the highest level of control and threat to public health. The most recently added 
synthetic cannabinoids to the DEA emergency Schedule I controlled substances list in 2013 
included XLR-11 and UR-144, among many other synthetic cannabinoids (Gurney et al., 2014). 
 
Figure 7. Molecular structures of XLR-11and UR-144 from Cayman Chemical (2014) 
Pharmacology of Synthetic Cannabinoids 
 In a very recent publication from Gurney et al. (2014), the pharmacology and toxicology 
of synthetic cannabinoids was studied in great depth, since a lack of information had been 
available about the pharmacology of these compounds. The CB1 and CB2 receptors are the main 
receptor of the endocannabinoid system. The CB1 receptor has been shown to be responsible for 
most of the psychotropic effects of Cannabis. The CB2 receptor serves as an immune modulator 
and the main target for therapeutic agents. Halogen-substituted synthetic cannabinoids, including 
XLR-11, often experience an increased binding affinity due to the halogenation of the synthetic 
cannabinoid side chain structure. For example, XLR-11 (5-fluoro-pentyl-UR-144) is the 
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fluorinated version of UR-144. Using in vivo animal studies, potency, spontaneous activity, 
among other characteristics were studied to understand how chemical structure, halogenated 
compounds versus non-halogenated, causes increases or decreases to the binding affinity of 
synthetic cannabinoids. In the study, UR-144 showed full agonist effects for both CB1 and CB2 
receptors, producing dose-dependent effects such as antinociception, hypothermia, catalepsy and 
suppression of locomotor activity. Results for XLR-11 proved to be similar. However, also 
reported was that the tetramethylcyclopropyl group confers selectivity for the CB2 receptor over 
the central CB1 receptor (Cayman Chemical, 2014).  
 An in-depth report for the World Health Organization (WHO) Expert Committee on Drug 
Dependence critically reviewed UR-144 and its chemistry, pharmacology, and toxicology. 
Drafted by Pennings along with other members of the World Health Organization (2014), 
binding affinities for UR-144 were generated by Abbott Laboratories for the WHO research 
effort. UR-144 showed a high binding affinity for both CB1 and CB2 receptors, being a highly 
CB2-selective ligand. Dosage-dependent effects were produced as a full agonist, which were 
blocked by the cannabinoid antagonist rimonabant in mice. A two-fold lower affinity of UR-144 
to the CB1 receptor as compared to THC may imply that UR-144 is less psychoactive than herbal 
Cannabis. This could lead to increased dosages by the user, and therefore unexpected side effects 
accompanying use of synthetic cannabinoids. 
In a presentation for the New Drugs 2014 conference in Rome, Italy, Moosmann et al. 
(2014) from the Institute of Forensic Medicine presented on the current known toxicity for 
synthetic cannabinoid receptor agonists. In particular, the researchers focused on many groups of 
synthetic cannabinoids containing the cyclopropylindoles, which UR-144 and XLR-11 belong to, 
as well as the indazole derivatives which contain AB-Pinaca and AB-Fubinaca. Moosmann et al. 
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(2014) provided information regarding the different instrumentation types and known receptor 
affinities for synthetic compounds, in comparison to natural Cannabis containing THC. Overall, 
lower doses of synthetic cannabinoids have stronger effects than THC, also showing strong 
maximum effects for CB receptor bindings. They have higher affinities and higher efficacies 
than Cannabis for CB receptor binding. 
Analysis of Synthetic Cannabinoids 
 Analytical efforts directed at synthetic cannabinoids have resulted in fundamental 
findings as to the chemical structure and binding affinities of these compounds.  In most of the 
JWH, CP, and AM series components, members differ mainly in the movement of one functional 
group or other small isomeric change to the chemical structure, but still result in the same or 
similar physiological effects.  Isomers as well as new molecules are being encountered in crime 
labs commonly, so many so that it is becoming difficult to keep up with the associated 
identification process.  The constantly evolving drug market finds new blends to manufacture 
while still being considered “legal.” In the expansive investigation by Logan et al. (2012), 
synthetic cannabinoid compounds were explored using several analytical techniques in an effort 
to determine which was the most effective. Liquid chromatography time-of-flight mass 
spectrometry proved to be the most useful technique, but is fairly new and is not usually utilized 
by all crime labs.  Gas chromatography tandem mass spectrometry was utilized by almost every 
study in the literature to determine the molecular weights of the involved compounds.  The 
literature discusses the difficulties faced by the forensic science field if more mass spectral data 
is not generated in response to the rapidly evolving field of synthetic cannabinoids.  From 
Logan’s analysis, the packages analyzed contained either one or two compounds, both of which 
were identifiable using the aforementioned analytical techniques.  However, new compounds are 
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continuously introduced in an effort to stay ahead of regulators. This evolution creates time 
constraint difficulties for forensic chemists in elucidating the structures of these compounds for 
the associated regulatory bodies.  
How synthetic cannabinoid plant material specimens are prepped for chemical analysis 
varies by the type of analysis to be undertaken, and the preferences and protocols of the 
laboratories conducting the analyses. In most instances, since the physical appearance of a 
synthetic cannabinoid product is a green, leafy, dry plant material.  Samples are often vortexed 
after the addition of an organic solvent, and then the chemical component containing the 
synthetic cannabinoid compounds is extracted into the organic solvent. This method is a simple 
and a typical preparation for follow-on analysis using gas chromatography tandem mass 
spectrometry.  The use of deuterated internal standards is important in validating the procedure 
for proper comparisons of chromatographic data.  The four options given when using 
chromatographic techniques are to use no internal standard, a structurally related compound, or  
a structurally similar compound or a stable isotope labeled compound, the latter three as internal 
standards. Internal standards are used to demonstrate that the extraction process from the 
biological sample was successful, as well as addressing any variations encountered in individual 
samples. Depending on the type of analysis and the degree of sample clean-up, an optimal 
internal standard can be selected.  Using past chromatographic data are also useful for comparing 
synthetic cannabinoid data, since the market is quickly evolving, standards and measurements 
are difficult to keep present.  
Synthetic cannabinoid compounds are detectable in blood, as determined in a study by 
Shanks, Dahn and Terrell (2012).  In “Determination of JWH-018 and JWH-073 by UPLC-MS-
MS in Postmortem Whole Blood Casework,” detailed experimental conditions are critical to note 
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for this research project (Shanks, Dahn & Terrell, 2012). The instrumental analysis and liquid-
liquid organic extraction procedure was imperative, since the study was performed on post-
mortem blood samples. Forensic toxicology labs are commonly given post-mortem samples to 
work with in an attempt to answer questions concerning cause of death, and they can often be 
more difficult than ante-mortem samples to work with due to clotting and other post-mortem 
effects such as putrefaction and microbial production. The study also validates their method for 
further applications of blood analysis of synthetic cannabinoids using LC-MS-MS.  Not only did 
the researchers validate their own methods, but they also analyzed three post-mortem cases. It 
was noted that peak concentration of synthetic cannabinoids in the blood stream is five minutes 
after administration of the drug, often inhalation through smoking, which poses the question to 
how long it will take these compounds to metabolize and degrade in biological samples, such as 
blood.  Also, this was one of the first few studies to detail post-mortem blood work for synthetic 
cannabinoid substances.  Shanks and Terrell were able to develop and validate a precise method 
that can identify JWH-018 and JWH-073 in human blood post-mortem. 
Dresen et al. (2011) were able to validate a method for LC-MS/MS analysis of synthetic 
cannabinoids in serum. This method utilized an alkaline liquid-liquid extraction analyzing for ten 
synthetic cannabinoids of interest. Freeze-and-thaw stability as well as long-term stability were 
performed with fortified serum samples, each of which were analyzed a week after initial 
fortification. Room temperature stability was analyzed using glass and polypropylene tubes to 
determine analyte stability in storage container conditions. Incorporating the liquid-liquid 
extraction with hexane and ethyl acetate proved to be the best extraction method to reduce matrix 
effects, which can often be problematic for electrospray ionization with LC-MS/MS. Results for 
stability showed that neither temperature condition affected the stability of the analytes for the 
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study’s one-week period. It was also shown that the stability of the analytes at room temperature 
in polypropylene and glass did not depend on the nature of the container. However, since all 
analytes showed stability at frozen conditions, it was recommended that samples should be 
shipped as well under these conditions.  This study also encompassed a forensic aspect, using 
known serum samples from patients of known synthetic cannabinoid use to determine the most 
prevalent parent compounds at the time of the study for forensic casework (Dresen et al., 2011).  
Kacinko et al. (2011) were able to validate a procedure for the identification and 
quantitation of synthetic cannabinoid compounds of interest in human whole blood. JWH-018, 
JWH-073, JWH-019, and JWH-250 were analyzed after spiking a whole blood with analytes and 
deuterated internal standards. Not only did the study validate a specific LC-MS/MS method, but 
also compiled a short stability study as a function of the storage conditions, chemical properties 
of the analyte, and the storage container. The stability timeline spanned 30 days and consisted of 
room temperatures, refrigerator, frozen and repeated freeze-thaw cycles. Ultimately, it was found 
that all analytes were stable for a minimum of 30 days under all conditions. Interferences, 
linearity, LOD, LOQ, matrix effects, and dilution integrity were all also assessed to ensure the 
validity of the methods developed. Along with validating a method for the analysis of synthetic 
cannabinoids via LC-MS/MS, proof of the method was also established by testing the blood of a 
known spice abuser to demonstrate applicability to forensic case work. 
Shanks, Dahn, and Terrell (2012) were able to develop and validate a method pertaining 
to synthetic cannabinoid analysis, and apply it to postmortem forensic casework. Applying a 
liquid-liquid extraction to postmortem blood is more difficult than extracting antemortem blood. 
The decomposition process can contribute to matrix issues associated with biological extraction 
processes. Decomposition contributes microbial contaminants and putrefaction products during 
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the breakdown processes. At the time of publishing, this was the first analytical method of its 
type, utilizing a liquid-liquid extraction including a hexane-ethyl acetate organic mixture. The 
use of a sodium carbonate buffer and the hexane-ethyl acetate mixture helped to stabilize the 
endogenous compounds produced in the decomposition process, such as metabolism products 
and biological matrix components that can often contaminate samples. This method was also 
applied to three cases encountered in laboratory work to quantitate JWH compounds prevalent at 
the time. 
In 2014, the above mentioned research group of Shanks et al. updated their extraction 
method to look for newer synthetic cannabinoid compounds. Using the same liquid-liquid 
extraction procedure from 2012, AB-Fubinaca, ADB-Pinaca, and PB-22 were quantitated in 
postmortem forensic samples. Due to their prevalence and emergency scheduling by the DEA, 
these newer compounds were added to the current method used at the time. This method was 
validated for the new compounds, and then applied to forensic casework as well using 
postmortem blood and serum. A substantial noted difference provided in the research was that 
newer compounds such as 5-F-PB-22 contain ester linkages, as compared to earlier compounds 
             
Figure 8. Molecular structures of AB-Fubinaca and AB-Pinaca from Cayman Chemical (2014) 
such as JWH-018 and XLR-11 that contain ketone linkages between the indole moiety and 
naphthoyl groups. It is suspected that the ester bond may be susceptible to in vivo hydrolysis 
STABILITY OF SYNTHETIC CANNABINOIDS  24 
 
reactions. This could cause accumulation of the metabolites producing toxic effects; however, 
more research would need to be done to further support these findings (Shanks et al. 2014).  
Degradation Studies and the Impact on Toxicology 
 From Clarke’s Analytical Forensic Toxicology (2013), drug stability in postmortem 
matrices poses an added level of difficulty in detection and quantification due to the 
decomposition products produced, as mentioned previously.  Blood specimens add a significant 
amount of other compounds besides the drug or analyte of interest.  Negrusz, Cooper and Clarke 
(2013) suggest that drug stability in blood should be evaluated in multiple schemes: long-term 
stability in the matrix of interest, the effect of freeze-thaw cycles, and short-term stability under 
multiple storage conditions (Negrusz, Cooper & Clarke, 2013).  To mimic the multiple storage 
conditions of evidentiary samples, the latter short-term stability monitoring will be explored for 
the duration of the present project.  Stability data on natural cannabinoids is also provided, 
comprising the information that cannabinoid concentrations in refrigerated as well as frozen 
conditions suffer from oxidative losses.  Since synthetic cannabinoids are made to mimic the 
structural effects of natural cannabinoids and thus often share structural similarities, this 
information could possibly also be applied to the synthetic cannabinoids.  Storage containers and 
conditions were extremely important when containing THC-cannabinoid samples as were housed 
for long periods of time.   
 The question of stability of analytes in biological samples being a large issue for forensic 
toxicology was raised in Peter’s review for the journal Analytical Bioanalytical Chemistty 
(2007).  To correctly determine the answer to this question, definitions and types of stability 
were clearly defined, that were compatible with the definitions set in Clarke’s Analytical 
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Forensic Toxicology.  An important point from Peter (2007) was that stability must also be 
regarded as a process where the result depends on two conditions: degradation of the analyte and 
its potential formation from precursor compounds (Peter, 2007).  Another key component to 
stability studies is comparing the results of quality-control samples analyzed before and after (the 
stability samples) being exposed to the conditions of interest.  Once again, cannabinoids were 
demonstrated to be susceptible to concentration losses due to oxidation and lipophilic binding to 
the storage container.  This will be important information to keep in mind for the duration of the 
project. 
 In a study by Giorgi and Meeker (1995), illicit drug stability was studied in blood 
samples.  The time period studied in this experiment was up to 5 years and included many drug 
compounds such as cocaine, benzoylecgonine, morphine, codeine, methamphetamine, 
amphetamine and phencyclidine.  While cannabinoids were not explored in this study as 
previously mentioned in the literature by Levine and Smith (1990), this study is integral to 
understanding the methodology and relevance of toxicological testing of the degradation issue 
faced when testing biological samples for illicit drugs.  In the forensic science lab these analyses 
can be performed using GC-MS, but currently with the growing popularity of liquid 
chromatography tandem mass spectrometry (LC-MS/MS), better sensitivity to analytes in 
biological specimens can be achieved.  
 Liquid chromatography tandem mass spectrometry has been explored for drug analysis in 
many studies since its emergence on the analytical analysis market roughly ten years ago.  In the 
publication by Sauvage et al. (2008), many relevant and helpful methods such as using stable-
isotope internal standards, establishing relative retention times, and using two transitions or more 
per compound were suggested when using LC-MS/MS for analysis.  Their experiments explored 
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previous false-positive tests and different methods of analysis for the best possible identification 
modes for drug analyses.  False-positive results are often noticed during toxicological analysis 
because of the metabolites or xenobiotics that are created after the body’s efforts to degrade such 
molecules.  Details of the results and keys to success using LC-MS/MS were clearly indicated in 
the work of Sauvage et al., but the importance of using the proper ion-monitoring mode was 
crucial to ensuring accurate results, rather than false-positive conclusions.  This study also 
demonstrates the importance of finding the best possible technique that is suited to the different 
cases of drug analysis.  As the researchers discovered, the high sensitivity of LC-MS/MS 
requires different monitoring modes (selected-reaction versus general unknown screening) for 
differing compounds.  Although the study analyzed atropine and lysergide compounds and their 
metabolites, and not synthetic cannabinoids, their analytical methods, suggestions and references 
are important to understanding LC-MS/MS methodology.  
Method validation for synthetic cannabinoid stability has not been studied in depth for 
liquid chromatography-tandem mass spectrometry using biological specimens, in specific whole 
blood and serum.  Dresen et al. (2010) performed freeze-thaw stability and long-term stability 
using spiked serum samples.  Overall, they found that the stability of the analytes stored at room 
temperature in glass and polypropylene tubes did not depend on the material of the container.  
Also, all of the tested compounds proved to be most stable under frozen conditions (-20°C). 
Specimens stored at room temperature suffered a slight degradation after a 72 hour period.  In 
Kneisel and Auwater’s (2012) analysis using liquid chromatography-electrospray ionization 
tandem mass spectrometry (LC/ESI-MS/MS), they analyzed for 30 synthetic cannabinoids in 
serum after using a liquid-liquid extraction technique.  Similar to Dresen’s (2010) study, freeze 
and thaw stability and long-term stability were tested. Their study was constructed in the same 
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fashion most stability studies are, using a specific time-schedule for analysis, individual 
temperature or environment conditions, and a spiked sample with the analytes of interest.   
 Stability studies begin with a designated set of analyte concentrations in the selected test 
medium, whether blood or serum, so that a concentration calibration curve can be generated.  
Then a known sample will be fortified with the analytes of interest.  The known concentration 
will be evaluated according to the schedule to track the stability or instability of the compounds 
due to analyte degradation.  Kacinko et al. (2010) were also able to develop a method for LC-
MS/MS identification and quantification of four JWH compounds using whole blood.  They 
found that analyte stability is a function of storage conditions, chemical properties of the analyte, 
the matrix and storage container.  A short and long term comparison was used for their study; 
however, their four JWH compounds analyzed were stable at room, refrigerated and frozen 
temperatures for 30 days.   
Summary 
 Having established a foundation for understanding the field of synthetic cannabinoids and 
how stability studies are designed, more information is needed on the stability of recently-
encountered synthetic cannabinoids. With the quickly-evolving market and turnover of new 
compounds, keeping up with these compounds is a difficult task in the laboratory setting. Few 
studies have been done to establish the stability of synthetic cannabinoid compounds. 
Furthermore, having an understanding as to how long these compounds are stable under various 
storage conditions would prove extremely useful for the forensic laboratory setting and the 
forensic chemistry and toxicology fields as a whole. 
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Materials and Methods 
Reagents and Standards 
All solvents and substances were at least of HPLC grade. EMD Omnisolve high purity 
HPLC-grade acetonitrile was purchased from VWR International (Radnor, Pennsylvania), while 
Optima LC/MS-grade Formic Acid, LCMS-grade hexanes, HPLC grade ethyl acetate and HPLC 
grade water were purchased from Fisher Scientific (Hampton, New Hampshire).  ACS-grade 
sodium bicarbonate and anhydrous sodium carbonate were also purchased from Fisher Scientific 
(Houston, TX) for sodium carbonate buffer preparation.  
One hundred µg/mL of AB-Fubinaca, XLR-11, and UR-144 in methanol were obtained 
from Cerilliant Corporation (Round Rock, TX). One hundred µg/mL of XLR-11-d5 in methanol, 
as well as solid preparations of 1.0 mg of AB-Pinaca and AB-Pinaca-d9 were purchased from 
Cayman Chemical (Ann Arbor, MI).   
The sodium carbonate buffer, pH 10.2, was prepared by adding 1.87 g of sodium 
bicarbonate and 0.29 g of sodium carbonate buffer salts to 250 mL of deionized (DI) water and 
adjusting the pH to 10.2 with 0.1M sodium hydroxide. Mobile phase A (0.1% formic acid in DI 
water) was prepared by adding 1.00 mL of concentrated optima formic acid to 1L of DI water. 
Mobile phase B (0.1% formic acid in acetonitrile) was prepared by adding 1.00 mL of formic 
acid to 1L of acetonitrile.  
Preparation of stock solutions 
Stock solutions (10 µg/mL) of each analyte of interest were prepared in acetonitrile from 
their 100 ug/mL original prepared concentrations. 
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Specimen collection 
 Date-expired human donor blood was donated to the OCME laboratory by the Oklahoma 
Blood Institute (OBI) and used in this study. Routine toxicological analyses for blood screening 
included immunoassay (ELISA) drug screen, alkaline drug screen and acid-neutral drug screen 
by an Agilent 5895C GC/MS to ensure absence of possible contaminants. A composite blood 
sample was stored under refrigerated conditions (4°C) until initial aliquots were made for 
stability test Day 0. Whole blood was preserved by the addition of sodium fluoride.   
 The control whole blood sample was spiked by adding 100 µL of each of the 10 µg/mL 
drug stock standards to 200 mL of the control whole blood. This resulted in 5.0 ng/mL of each 
analyte of interest. The spiked sample was then aliquotted out individually for three storage 
conditions, containing ten tubes of approximately 5 mL of the composite blood sample. 
Preparation of working solutions 
Working solutions were made for calibration curves ranging from 0.1 ng/mL to 10.0 
ng/mL.  A 50 ng/mL internal standard working solution was prepared consisting of XLR-11-d5 
and AB-Pinaca-d9 in acetonitrile. A seven point calibration curve was prepared using the 
following concentrations: 0.1, 0.25, 0.5, 1.0, 2.5, 5.0, and 10.0 ng/mL. Low-and high-
concentration quality control samples were prepared containing all of the 4 compounds. Quality 
control working stocks were prepared at 5 ng/mL and 50 ng/mL in acetonitrile. Sample 
preparation involved adding 100 µL of each QC working solution to 1.0 mL of blood, yielding 
extracted concentrations of 0.5 ng/mL and 5.0 ng/mL. Linearity, accuracy, bias, and precision 
were determined from QC and calibration curve data. 
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Sample preparation and extraction 
For analysis, 100 µL of deuterated internal standards were pipetted into the bottom of a 
15 mL screw cap tube. One milliliter of sample blood was transferred to the tube.  One milliliter 
of the pH 10.2 sodium carbonate buffer (pH 10.2) was added, then vortexed well. Following this, 
5.0 mL of an 80:20 (v/v) hexanes and ethyl acetate mixture were added to the sample. Specimens 
were vigorously shaken by hand 20 times. They were then placed on a rotor-extractor for 10 
minutes. The specimens were then centrifuged at 3,000 rpm for 10 minutes. Subsequently, the 
organic supernatant was transferred to a 7.0 mL glass conical vial and evaporated to dryness 
under a gentle stream of dry nitrogen at 40°C. The dry study specimens were reconstituted with 
200 µL of a 50:50 (v/v) 0.1% formic acid in water and 0.1% formic acid in acetonitrile mixture. 
Samples were then vortexed, syringe filtered through a 0.2 µm Titan filter, and transferred to 
glass auto-sampler vials. 
Liquid chromatography-electrospray ionization tandem mass spectrometry (LC/ESI-
MS/MS) 
The LC-ESI-MS/MS system employed in this study consisted of an Agilent 6420 triple-
quadrupole mass spectrometer paired with an Agilent 1290 Infinity series liquid chromatography 
system, which used a G4226A auto-sampler, G4204A quaternary pump, and a G1316A 
thermostat-regulated column compartment.  
 
Figure 9. Fragmentation Schematic of LC/MS/MS based on Ni and Rowe (2012) 
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Figure 10. Agilent LC/MS/MS system used in study 
A Restek Ultra-C18 5µm, 50x2.1 mm HPLC column was utilized because of its common 
acceptance and usage with polar mobile phases. Three ion transitions were monitored using a 
multiple-reaction monitoring (MRM) method. The parent and qualifier ions used for monitoring 
are listed in Table 1. 
Instrument Conditions 
 An 8.5 minute run time with a post time of 1.4 minutes utilized positive (+) Electrospray 
Ionization and a multiple reaction monitoring scanning mode. A 10 µL injection with a 10 
mL/min flow of 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B); the 
column compartment was regulated at 40°C while source gas was kept at 350°C. Capillary 
voltage was at 400 volts. Gradient control is stated in Table 2. 
Table 1 
Gradient Flow LC Conditions in study 
Time (min) % Mobile Phase A % Mobile Phase B 
0.0 70% 30% 
1.5 40% 60% 
7.0 10% 90% 
8.5 70% 30% 
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Scan Segments along with other experimental instrumental controls are included in Table 2. 
Table 2 
Fragmentation Patterns and Instrumental Conditions in study 
 
*Dwell time is the amount of time required for the MS to analyze a single MRM transition 
**Fragmentor voltage the energy required to fragment precursor ions into product/qualifier ions 
***Collision energy is the amount of energy that precursor ions receive as they are accelerated to the 
collision cell, where they collide with gas molecules and fragment 
****Cell Acceleration the electric potential that excels ions through the collision quadrupole 
 
LOD/LOQ, Carryover, Precision, and Bias Studies 
 Studies were performed to determine limit of detection (LOD), limit of quantitation 
(LOQ), carryover, precision and bias. LOD and LOQ were evaluated making serial dilutions 
with concentrations ranging from 0.0125 to 0.10 ng/mL. These concentrations are lower than 
those used for the calibrators. The samples were extracted from control blood using the same 
liquid-liquid extraction technique for the study specimens. Requirements for validation criteria 
are included in the respective results section for each validation area.   
Compound Name ISTD Precursor Ion Product Ion Dwell Time (s)* Fragment (V)** CE (V)*** Cell Acc (V) **** Polarity
AB-Fubinaca No 369.2 324.1 50 95 10 7 Positive
AB-Fubinaca No 369.2 253 50 95 22 7 Positive
AB-Fubinaca No 369.2 109 50 95 50 7 Positive
AB-Pinaca-d9 Yes 340.3 295.2 50 100 14 7 Positive
AB-Pinaca-d9 Yes 340.3 224.1 50 100 26 7 Positive
AB-Pinaca-d9 Yes 340.3 146 50 100 38 7 Positive
XLR-11-d5 Yes 335.3 236.7 50 154 26 7 Positive
XLR-11-d5 Yes 335.3 125 50 154 22 7 Positive
XLR-11-d5 Yes 335.3 55.1 50 154 46 7 Positive
AB-Pinaca No 331.2 286.1 50 100 10 7 Positive
AB-Pinaca No 331.2 215.1 50 100 22 7 Positive
AB-Pinaca No 331.2 145 50 100 46 7 Positive
XLR-11 No 330.2 232 50 149 22 7 Positive
XLR-11 No 330.2 125 50 149 22 7 Positive
XLR-11 No 330.2 55.1 50 149 46 7 Positive
UR-144 No 312.2 214 50 159 22 7 Positive
UR-144 No 312.2 125 50 159 22 7 Positive
UR-144 No 312.2 55.1 50 159 42 7 Positive
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Specificity testing 
Specificity analysis was done by spiking control blood with drugs that expected to cause 
interferences. These drugs would be of similar class and/or of similar structural nature. The test 
included 20 alkaline drugs commonly detected, 9 acidic or neutral drugs, as well as using 3 
different synthetic cannabinoid mixes purchased from Cerilliant Corporation (Round Rock, TX). 
Ten nanograms of each mix was extracted after fortifying control blood with the following 
compounds contained in Table 4. 
Table 3 
Alkaline drugs and Acidic/Neutral drugs Tested 
Alkaline drugs Acidic/Neutral Drugs 
Methamphetamine Valproate 
Pseudoephedrine Ibuprofen 
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Table 4 
Synthetic Cannabinoid Test Mixes Purchased from Cerillant Co. (2014) 
Synthetic Mix #1 Synthetic Mix #2 Synthetic Mix #3 
JWH-250 JWH-019 JWH-015 
JWH-200 JWH-122 JWH-203 
HU-211 JWH-081 JWH-210 
(+) CP-47, 497 AM-2201 AM-2233 
(-) CP-47, 497 RCS-4  
C8 Homologue RCS-8  
  
Matrix Effects/ Ion Supression or Enhancement 
 Matrix effects (ion suppression or ion enhancement) were studied using 10 synthetic 
cannabinoid negative, post-mortem bloods stored for method development purposes. The 
analyses were performed by adding 100 µL of the 50.0 ng/mL of the working quality control 
solution as well as 100 µL of the 50.0 ng/mL of the internal standard working solution to whole 
blood blank vials, following the extraction process. These samples were compared to the “neat” 
vial, which contained only internal standard and 5.0 ng/mL of QC that was evaporated to 
dryness, and reconstituted. The matrix recovery and efficiency was calculated based upon the 
pre-extraction spiking recovery and the post-extraction spiking recovery.  
Benchtop Stability 
 For validation purposes, benchtop stability was assessed to test for any possible 
contaminants or possible quality control degradation. This was achieved by using one set of 
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QC’s from a previous run, allowing said QC’s to sit at ambient temperature for 72 hours, then 
analyzing the same QC’s with a new calibration curve. No stability or degradation issues were 
detected in the quality controls over the 72 hour period.  
Stability Timeline and Preparation 
 Study timeline was set to span twelve weeks. Samples were stored under three 
temperature conditions, ambient temperature (~22°C), refrigerator temperature (4°C), and freezer 
conditions (-20°C).  On study day 0, 200 mL of a human, whole blood sample was spiked with 
100 µL of each drug standard, for a final concentration of 5.0 ng/mL for each analyte of interest. 
Specimens for the three temperature conditions were aliquotted out for the 11 proposed study 
days, plus an additional three tubes for safety, equaling 42 total test tubes. Fourteen individual 
16x100 mm borosilicate glass test tubes, secured with polypropylene screw caps, for each 
temperature condition. Stability test was performed on Study days: Day 0, 3, 7, 14, 21, 28, 35, 
42, 56, 70, and 84.  
Data Analysis and Statistics 
 The descriptive statistics used were means, standard deviation, and coefficient of 
variation. Data plots were used to determine the estimated rate of decay, as well as to calculate 









 Linearity, precision between and within runs, ion suppression/enhancement, and bias 
were calculated by using 5 consecutive runs of calibration curves, low, and high concentration 
quality control samples. Validation procedures and requirements come from those established by 
the Scientific Working Group for Toxicology (SWGTOX, 2013)  and are also required by the 
American Board of Forensic Toxicology (ABFT). 
Limit of Detection/Limit of Quantitation 
 Limit of quantitation was established at 0.1 ng/mL after running test calibration curves 
for all compounds to determine how low concentrations could range and still meet the required 
criteria. LOQ requires integration of a parent and daughter ion, as well as a signal to noise ratio 
of 10:1. LOD was determined by diluting several curve points below the established LOQ. This 
was found to be 0.025 ng/mL for all compounds. LOD requires the integration of one parent and 
one daughter ion, as well as a signal to noise ratio of 3:1.  
Linearity 
Five independent calibration curve runs were all pooled and averaged, as well as 
calculating the percent coefficient of variation for each analyte. For linearity, R2 values for curve 
fit required at least a 0.99 value, as well as a coefficient of variation (CV) value less than 10%.  
It is also required that each calibration curve point for each analyte can not deviate beyond 20% 
from the targeted value. All four drugs analyzed during the validation period met the linearity 
requirements. 
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Table 5 








Figure 11. Linearity Plot for AB-Fubinaca (All runs included) 
 
9/16/2014 9/23/2014 9/30/2014 10/7/2014 10/21/2014
Concentration Run 1 Run 2 Run 3 Run 4 Run 5 Average SD CV
0.10 0.11 0.11 0.11 0.12 0.12 0.11 0.01 4.8%
0.25 0.24 0.26 0.25 0.25 0.24 0.25 0.01 3.4%
0.50 0.50 0.47 0.50 0.45 0.46 0.48 0.02 4.8%
1.00 0.95 0.91 0.91 0.89 0.90 0.91 0.02 2.5%
2.50 2.43 2.40 2.53 2.53 2.41 2.46 0.06 2.6%
5.00 5.14 5.29 5.20 4.95 5.28 5.17 0.14 2.7%
10.00 9.99 9.91 9.85 10.16 9.93 9.97 0.12 1.2%
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Table 6 







Figure 12. Linearity Plot for AB-Pinaca (All runs included) 
 
 
9/16/14 9/23/14 9/30/14 10/7/2014 10/21/14
Concentration Run 1 Run 2 Run 3 Run 4 Run 5 Average SD CV
0.10 0.12 0.11 0.12 0.12 0.12 0.12 0.00 3.8%
0.25 0.24 0.27 0.25 0.24 0.25 0.25 0.01 4.9%
0.50 0.46 0.46 0.46 0.45 0.44 0.45 0.01 2.0%
1.00 0.96 0.98 0.92 0.92 0.96 0.95 0.03 2.8%
2.50 2.45 2.35 2.39 2.57 2.40 2.43 0.08 3.5%
5.00 5.01 5.11 5.07 4.97 4.95 5.02 0.07 1.3%
10.00 10.12 10.08 10.15 10.08 10.23 10.13 0.06 0.6%
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Table 7 







Figure 13. Linearity Plot for UR-144 (All runs included) 
 
 
9/16/14 9/23/14 9/30/14 10/7/14 10/21/14
Concentration Run 1 Run 2 Run 3 Run 4 Run 5 Average SD CV
0.10 0.12 0.11 0.12 0.10 0.12 0.11 0.01 7.8%
0.25 0.23 0.25 0.24 0.24 0.24 0.24 0.01 2.9%
0.50 0.44 0.49 0.48 0.51 0.47 0.48 0.03 5.4%
1.00 0.99 0.91 0.90 0.98 0.93 0.94 0.04 4.3%
2.50 2.47 2.49 2.43 2.60 2.42 2.48 0.07 2.9%
5.00 5.15 5.03 4.98 4.79 5.03 5.00 0.13 2.6%
10.00 9.95 10.08 10.21 10.13 10.14 10.10 0.10 1.0%
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Table 8 







Figure 14. Linearity Plot for XLR-11 (All runs included) 
 
 
9/16/14 9/23/14 9/30/14 10/7/14 10/21/14
Concentration Run 1 Run 2 Run 3 Run 4 Run 5 Average SD CV
0.10 0.12 0.11 0.12 0.12 0.12 0.12 0.00 3.8%
0.25 0.23 0.25 0.24 0.23 0.24 0.24 0.01 3.5%
0.50 0.49 0.49 0.47 0.49 0.45 0.48 0.02 3.7%
1.00 0.95 0.93 0.94 0.91 0.99 0.94 0.03 3.1%
2.50 2.49 2.43 2.39 2.46 2.37 2.43 0.05 2.0%
5.00 5.01 4.90 5.02 5.01 5.04 5.00 0.06 1.1%
10.00 10.07 10.24 10.17 10.13 10.14 10.15 0.06 0.6%
STABILITY OF SYNTHETIC CANNABINOIDS  41 
 
Precision 
 Precision was calculated and compared by using the two extracted levels of QC, 0.5 
ng/mL and 5.0 ng/mL, and calculating the mean, standard deviations, and percentage of 
coefficient variation from the rough data for five runs. The percent coefficient variation limit was 
cutoff at 10%. Precision was calculated between run and within run for two levels of QC.  
Within-run precision is calculated for each concentration separately for each of the five runs 
using each triplicate. Between-run is calculated from the combined data from all replicates of 
each concentration level. The coefficients of variation calculated for precision must be less than 
10%. Between-Run data collected is included in Table 9 (a-d), within-run data is included in 
Appendix C.  
   
Table 9 (a-d) 
Precision Data and Bias Percentages Between-Run for all compounds 
  AB-Fubinaca (a)                                                     AB-Pinaca (b) 
       



















% CV 6.76% 3.96%
% CV Limit <10 % <10 %
% Bias (Avg) Level I
% Bias Limit

























% CV 5.75% 3.99%
% CV Limit <10 % <10 %
% Bias (Avg) Level I
% Bias Limit
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            UR-144 (c)      XLR-11 (d) 
       
 Within run precision was also calculated by taking each replicate for every drug, and 
calculating the highest %CV along with descriptive statistics. All % CV’s were within the 
required limit for the method validation.  
Bias  
 Bias percentage was calculated for each level of quality controls for each drug, requiring 
that bias must be less than 20%. This calculation was done by comparing the calculated value to 
the expected level of the control. All bias percentages were less than 20%, except for AB-Pinaca, 
which at the current time is an unexplained phenomenon. A secondary set of quality controls was 
freshly prepared after this discovery and compared to the previous used QC’s in an attempt to 
eliminate bias. However, the calculated results for the new QC’s were still on the lower range of 
values, similar to the previous QC. While the bias issue has been identified, due to the fact that 
there are no other outside sources to verify this quantification problem, the compound may still 
be screened using the established method.  AB-Pinaca cannot be further validated for 



















% CV 9.09% 5.76%
% CV Limit <10 % <10 %
% Bias (Avg) Level I
% Bias Limit

























% CV 4.84% 3.49%
% CV Limit <10 % <10 %
% Bias (Avg) Level I
% Bias Limit
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quantification purposes due to the bias percentage lying outside of the required range. These 
validation criteria are based on the criteria and purposes of validation for the Office of the Chief 
Medical Examiner.  
Carryover 
 Carryover was assessed by spiking a control blood sample with 100 ng of each analyte of 
interest, which is a ten-fold increase from the used highest calibrator sample. Defined as the 
appearance of unintended analyte signal in subsequent samples following a positive, a blank 
sample was run following the carryover spike to detect any possible contaminants. No carryover 
was detected on following samples or blanks.  
Matrix Effects/ Ion Suppression or Enhancement 
 Matrix effects (ion suppression or ion enhancement) were studied using 10 synthetic 
cannabinoid negative, post-mortem bloods stored for method development purposes. This 
analysis monitors for any direct or indirect interference in the instrument response. The analyses 
were performed by adding 100 µL containing 50.0 ng of the working quality control as well as 
100 µL containing 50.0 ng of working internal standard to whole blood blank vials, following the 
extraction process. These samples were compared to the “neat” vial, which contained only 
internal standard and 5.0 ng QC that was evaporated to dryness, and reconstituted. The matrix 
recovery and efficiency was calculated based upon the pre-extraction spiking recovery and the 
post-extraction spiking recovery. Overall, all analytes demonstrated good recovery and matrix 
percentages; however, UR-144 suffered from unexplainable matrix effects. The quantification 
ion (parent ion) as well as two qualifier ions was monitored for matrix effects when compared to 
the “neat” vial for pre- and post-extraction additions. Data is presented in Tables 10-13.  
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Table 10 





Neat Pre-Extraction Post-Extraction Matrix Recovery Efficiency
44994
Blood 1 44994 28824 36223 80.51% 79.57% 64.06%
Blood 2 44994 32569 30442 67.66% 106.99% 72.39%
Blood 3 44994 34501 33258 73.92% 103.74% 76.68%
Blood 4 44994 32639 40736 90.54% 80.12% 72.54%
Blood 5 44994 31126 41435 92.09% 75.12% 69.18%
Blood 6 44994 26694 46471 103.28% 57.44% 59.33%
Blood 7 44994 30124 48107 106.92% 62.62% 66.95%
Blood 8 44994 31346 45408 100.92% 69.03% 69.67%
Blood 9 44994 33192 41354 91.91% 80.26% 73.77%
Blood 10 44994 34870 38007 84.47% 91.75% 77.50%
Average 89.22% 80.66% 70.21%
Standard Dev. 12.75% 16.26% 5.64%
% CV 14.29% 20.16% 8.03%
AB-FUBINACA (Qual1)
Neat Pre-Extraction Post-Extraction Matrix Recovery Efficiency
40456
Blood 1 40456 26125 32193 79.58% 81.15% 64.58%
Blood 2 40456 34309 29193 72.16% 117.52% 84.81%
Blood 3 40456 32607 30740 75.98% 106.07% 80.60%
Blood 4 40456 28800 36247 89.60% 79.45% 71.19%
Blood 5 40456 28699 37257 92.09% 77.03% 70.94%
Blood 6 40456 24240 43368 107.20% 55.89% 59.92%
Blood 7 40456 27351 43228 106.85% 63.27% 67.61%
Blood 8 40456 29090 41807 103.34% 69.58% 71.91%
Blood 9 40456 30150 38427 94.98% 78.46% 74.53%
Blood 10 40456 30355 35261 87.16% 86.09% 75.03%
Average 90.89% 81.45% 72.11%
Standard Dev. 12.52% 18.52% 7.27%
% CV 13.77% 22.73% 10.08%
AB-FUBINACA (Qual2)
Neat Pre-Extraction Post-Extraction Matrix Recovery Efficiency
48825
Blood 1 48825 30505 37167 76.12% 82.08% 62.48%
Blood 2 48825 34309 32567 66.70% 105.35% 70.27%
Blood 3 48825 37158 35267 72.23% 105.36% 76.10%
Blood 4 48825 33891 41958 85.94% 80.77% 69.41%
Blood 5 48825 34635 41997 86.02% 82.47% 70.94%
Blood 6 48825 29166 48329 98.98% 60.35% 59.74%
Blood 7 48825 31144 50289 103.00% 61.93% 63.79%
Blood 8 48825 32779 47956 98.22% 68.35% 67.14%
Blood 9 48825 34310 42935 87.94% 79.91% 70.27%
Blood 10 48825 35957 38784 79.43% 92.71% 73.64%
Average 85.46% 81.93% 68.38%
Standard Dev. 12.07% 15.88% 5.10%
% CV 14.12% 19.38% 7.46%
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Table 11 





Neat Pre-Extraction Post-Extraction Matrix Recovery Efficiency
78984
Blood 1 78984 54427 53922 68.27% 100.94% 68.91%
Blood 2 78984 55992 46539 58.92% 120.31% 70.89%
Blood 3 78984 62250 47675 60.36% 130.57% 78.81%
Blood 4 78984 58495 62483 79.11% 93.62% 74.06%
Blood 5 78984 50986 64946 82.23% 78.51% 64.55%
Blood 6 78984 55525 78982 100.00% 70.30% 70.30%
Blood 7 78984 51506 74605 94.46% 69.04% 65.21%
Blood 8 78984 55731 73666 93.27% 75.65% 70.56%
Blood 9 78984 60283 66626 84.35% 90.48% 76.32%
Blood 10 78984 55812 57813 73.20% 96.54% 70.66%
Average 79.42% 92.60% 71.03%
Standard Dev. 14.22% 20.65% 4.46%
% CV 17.91% 22.30% 6.28%
AB-PINACA (Qual1)
Neat Pre-Extraction Post-Extraction Matrix Recovery Efficiency
46519
Blood 1 46519 35604 34026 73.14% 104.64% 76.54%
Blood 2 46519 35548 28842 62.00% 123.25% 76.42%
Blood 3 46519 40064 31029 66.70% 129.12% 86.12%
Blood 4 46519 37101 38529 82.82% 96.29% 79.75%
Blood 5 46519 32850 39283 84.45% 83.62% 70.62%
Blood 6 46519 64547 49937 107.35% 129.26% 138.75%
Blood 7 46519 32209 47274 101.62% 68.13% 69.24%
Blood 8 46519 34995 47618 102.36% 73.49% 75.23%
Blood 9 46519 36782 40731 87.56% 90.30% 79.07%
Blood 10 46519 36623 36321 78.08% 100.83% 78.73%
Average 84.61% 99.89% 83.05%
Standard Dev. 15.42% 22.01% 20.14%
% CV 18.22% 22.04% 24.25%
AB-PINACA (Qual2)
Neat Pre-Extraction Post-Extraction Matrix Recovery Efficiency
42768
Blood 1 42768 31910 31721 74.17% 100.60% 74.61%
Blood 2 42768 32722 27224 63.66% 120.20% 76.51%
Blood 3 42768 35735 28540 66.73% 125.21% 83.56%
Blood 4 42768 34209 35723 83.53% 95.76% 79.99%
Blood 5 42768 29848 35937 84.03% 83.06% 69.79%
Blood 6 42768 31261 45623 106.68% 68.52% 73.09%
Blood 7 42768 30062 42999 100.54% 69.91% 70.29%
Blood 8 42768 31259 43374 101.42% 72.07% 73.09%
Blood 9 42768 33238 37699 88.15% 88.17% 77.72%
Blood 10 42768 32475 33213 77.66% 97.78% 75.93%
Average 84.66% 92.13% 75.46%
Standard Dev. 14.73% 19.86% 4.26%
% CV 17.40% 21.56% 5.64%
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Table 12 





Neat Pre-Extraction Post-Extraction Matrix Recovery Efficiency
193829
Blood 1 193829 65296 48775 25.16% 133.87% 33.69%
Blood 2 193829 67550 56433 29.11% 119.70% 34.85%
Blood 3 193829 103523 51217 26.42% 202.13% 53.41%
Blood 4 193829 77520 63267 32.64% 122.53% 39.99%
Blood 5 193829 69771 95235 49.13% 73.26% 36.00%
Blood 6 193829 96877 110932 57.23% 87.33% 49.98%
Blood 7 193829 71089 64800 33.43% 109.71% 36.68%
Blood 8 193829 121453 107662 55.54% 112.81% 62.66%
Blood 9 193829 79405 43520 22.45% 182.46% 40.97%
Blood 10 193829 116206 75354 38.88% 154.21% 59.95%
Average 37.00% 129.80% 44.82%
Standard Dev. 12.74% 40.09% 10.82%
% CV 34.44% 30.88% 24.14%
UR144 (Qual1)
Neat Pre-Extraction Post-Extraction Matrix Recovery Efficiency
38732
Blood 1 38732 20231 10514 27.15% 192.42% 52.23%
Blood 2 38732 14001 12242 31.61% 114.37% 36.15%
Blood 3 38732 21266 10758 27.78% 197.68% 54.91%
Blood 4 38732 15975 13033 33.65% 122.57% 41.24%
Blood 5 38732 14411 20289 52.38% 71.03% 37.21%
Blood 6 38732 20926 21940 56.65% 95.38% 54.03%
Blood 7 38732 14449 13255 34.22% 109.01% 37.31%
Blood 8 38732 25227 21432 55.33% 117.71% 65.13%
Blood 9 38732 16958 9846 25.42% 172.23% 43.78%
Blood 10 38732 23187 15223 39.30% 152.32% 59.87%
Average 38.35% 134.47% 48.19%
Standard Dev. 12.07% 42.33% 10.39%
% CV 31.46% 31.48% 21.55%
UR144 (Qual2)
Neat Pre-Extraction Post-Extraction Matrix Recovery Efficiency
77337
Blood 1 77337 39247 20502 26.51% 191.43% 50.75%
Blood 2 77337 27333 24125 31.19% 113.30% 35.34%
Blood 3 77337 39631 22835 29.53% 173.55% 51.24%
Blood 4 77337 30734 27131 35.08% 113.28% 39.74%
Blood 5 77337 27877 39111 50.57% 71.28% 36.05%
Blood 6 77337 39160 45597 58.96% 85.88% 50.64%
Blood 7 77337 28625 28308 36.60% 101.12% 37.01%
Blood 8 77337 46910 44664 57.75% 105.03% 60.66%
Blood 9 77337 31728 20055 25.93% 158.20% 41.03%
Blood 10 77337 46411 32905 42.55% 141.05% 60.01%
Average 39.47% 125.41% 46.25%
Standard Dev. 12.44% 39.14% 9.66%
% CV 31.52% 31.21% 20.88%
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Table 13 





Neat Pre-Extraction Post-Extraction Matrix Recovery Efficiency
116343
Blood 1 116343 84507 54306 46.68% 155.61% 72.64%
Blood 2 116343 84427 60954 52.39% 138.51% 72.57%
Blood 3 116343 105881 52826 45.41% 200.43% 91.01%
Blood 4 116343 86527 66976 57.57% 129.19% 74.37%
Blood 5 116343 80782 82277 70.72% 98.18% 69.43%
Blood 6 116343 93234 104862 90.13% 88.91% 80.14%
Blood 7 116343 78247 74020 63.62% 105.71% 67.26%
Blood 8 116343 100216 97612 83.90% 102.67% 86.14%
Blood 9 116343 81482 54223 46.61% 150.27% 70.04%
Blood 10 116343 103022 77335 66.47% 133.22% 88.55%
Average 62.35% 130.27% 77.21%
Standard Dev. 15.73% 33.58% 8.62%
% CV 25.23% 25.78% 11.16%
XLR11 (Qual1)
Neat Pre-Extraction Post-Extraction Matrix Recovery Efficiency
36520
Blood 1 36520 28518 17410 47.67% 163.80% 78.09%
Blood 2 36520 27254 19561 53.56% 139.33% 74.63%
Blood 3 36520 34339 17797 48.73% 192.95% 94.03%
Blood 4 36520 28799 22029 60.32% 130.73% 78.86%
Blood 5 36520 26376 25927 70.99% 101.73% 72.22%
Blood 6 36520 29539 34972 95.76% 84.46% 80.88%
Blood 7 36520 24759 23589 64.59% 104.96% 67.80%
Blood 8 36520 32327 30347 83.10% 106.52% 88.52%
Blood 9 36520 24926 17909 49.04% 139.18% 68.25%
Blood 10 36520 32827 23213 63.56% 141.42% 89.89%
Average 63.73% 130.51% 79.32%
Standard Dev. 15.88% 32.41% 9.09%
% CV 24.91% 24.84% 11.47%
XLR11 (Qual2)
Neat Pre-Extraction Post-Extraction Matrix Recovery Efficiency
46415
Blood 1 46415 34204 22077 47.56% 154.93% 73.69%
Blood 2 46415 33010 24778 53.38% 133.22% 71.12%
Blood 3 46415 42392 21488 46.30% 197.28% 91.33%
Blood 4 46415 34744 27496 59.24% 126.36% 74.86%
Blood 5 46415 32174 33140 71.40% 97.09% 69.32%
Blood 6 46415 36998 43372 93.44% 85.30% 79.71%
Blood 7 46415 31438 30799 66.36% 102.07% 67.73%
Blood 8 46415 40547 40031 86.25% 101.29% 87.36%
Blood 9 46415 33019 22210 47.85% 148.67% 71.14%
Blood 10 46415 41626 30231 65.13% 137.69% 89.68%
Average 63.69% 128.39% 77.59%
Standard Dev. 16.34% 33.73% 8.86%
% CV 25.65% 26.27% 11.42%
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Stability and Degradation Results 
 Stability samples were run on each of the study days for the three temperature conditions 
in triplicate. The data was then pooled and descriptive statistics such as mean, standard 
deviation, and the coefficient of variation was calculated for each drug in the appropriate 
condition. These results were graphed to assess degradation trending, so that the order of kinetic 
degradation along with half-life or “shelf life” could be determined for each drug. The 
percentage of degradation was also calculated based on the initial concentrations of each analyte 
from the Study Day 0 findings. Below is an example MRM chromatogram of the 10.0 ng/mL 
standard to demonstrate peak shapes and elution times, as well as ion monitoring modes for AB-
Fubinaca, AB-Pinaca, XLR-11, and UR-144, along with the two deuterated internal standards. 
Deuterated internal standards, AB-Pinaca-d9
 and XLR-11-d5, will elute at the same or close 
retention time to their similar compounds. Because of the highly specific and sensitive 
monitoring of the specific ionization ranges for each compound, there is a small window for 
retention time for each compound. 
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Figure 17. Ambient Temperature Storage Data  
 From the data plot above for ambient conditions (22°C), it can be noted that the trendline 
for XLR-11 follows a first-order decay scheme based on the exponential trendline. The equation 
for the line given can be used to extrapolate the approximate day that XLR-11 would reach the 
LOQ established for the study. Based on this knowledge, the time it would take for XLR-11 to 
reach 0.10 ng/mL, or the established LOQ for the study method would be 85.16 days, just shortly 
after the end of study.  All of the drugs showed to be relatively stable in ambient conditions. 
XLR-11 was the only drug that showed significant degradation at ambient conditions. First-order 
reaction rates do not vary with increasing or decreasing reactant concentrations. The rate of the 
degradation reaction is equal to the constant of the reaction. An approximate half-life or “shelf-
life” can also be calculated from the degradation generated using the equation: Nt = N0(1/2)t/t1/2.  
The equation variables indicate that Nt is the quantity remaning after a time (t),  N0 is the initial 
quantity of analyte, and t½ is the half life. XLR-11 in ambient conditions has an approximate 
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half-life of 17.19 days under these conditions until half of the initial concentration is eliminated. 
This calculation is based on the initial concentration of analyte, the final concentration, and the 
time point since the initial, which was the 84th final study day.  
 
Figure 18. Refrigerated Storage Condition Data  
 Refrigerated conditions suffered from less degradative effects, however XLR-11 was still 
degrading at refrigerated conditions (4°C). Based on the exponential equation of the trendline for 
XLR-11 data in refrigerated conditions, the approximate time  to reach the LOQ was calculated. 
The time required to reach 0.10 ng/mL would be 249.71 days. The approximated half-life 
calculated for XLR-11 under refrigerated conditions would be 26.99 days, longer than ambient 
conditions.  
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Figure 19. Frozen Storage Condition Data 
 Frozen conditions (-20°C) showed stabilization of all analytes, which results in it being 
the suggested medium for storage of biological samples containing suspected synthetic 
cannabinoids.   
 The percentages of degradative loss were calculated based on the initial Day 0 ambient 
concentrations for all of the monitored compounds. These calculations were based on the 
averaged concentrations, per analyte, for each condition at the 3, 6, and 12 week time points. The 
percentages of degradative loss are insignificant for all analytes except XLR-11, which clearly 
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Table 14. 
Percent Loss Calculated Table for all compounds of interest 
 
Discussion 
 Stability studies have been used for a great deal of time to determine shelf life for 
prescription or illicit drugs, proving to be advantageous for the chemist or toxicologist dealing 
with stability of samples. In further detail, drug stability can be altered or affected by many 
different conditions which include characteristics of the matrix, physicochemical properties, 
metabolism pathways, container selection, addition of preservatives, and storage temperature. 
Furthermore, drug stability can suffer even more in biological matrices, especially when post-
mortem processes due to putrefaction and microbial invasion interfere. However, most forensic 
laboratories deal with ante-mortem or post-mortem samples, leaving the biological properties a 
common factor when understanding how drugs or analytes degrade in the specimen. Controlling 
the highest number of possible variables is crucial to conducting stability studies. Storage 
conditions are usually the most crucial variable, and are commonly used for drug stability 
studies. Understanding the stability or instability of analytes and how they are impacted by 
temperature or storage condition, provides the chemist or toxicologist with knowledge as to how 
Week 3 Week 6 Week 12
AB-Fubinaca 6.92% 5.55% -3.42%
5.03% 6.82% -3.93%
2.16% 4.97% -5.55%
AB-Pinaca 4.09% 3.18% 4.18%
4.19% 3.43% 3.28%
3.97% 3.71% 3.91%
UR-144 1.01% 2.28% 1.63%
-2.34% -3.70% -4.92%
1.91% 4.23% -7.50%
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specimens should be treated, under what conditions, and what time window they have to work 
with, before detrimental losses to the analyte are encountered.  
The four compounds chosen for the project were recently noticed in forensic physical 
evidence sampling at the Office of the Chief Medical Examiner, and were also lacking of 
published data regarding their stability; therefore, AB-Fubinaca, AB-Pinaca, XLR-11, and UR-
144 were chosen to be monitored.  One of the outcomes to this project, along with the stability 
data generated, was the validated procedure used to extract and identify the four investigated 
synthetic cannabinoid compounds. All of the compounds were tested and analyzed in the areas of 
linearity, bias, precision, matrix effects, LOD/LOQ, bench top stability, specificity, and 
carryover. Establishing and validating the extraction method used for this project was necessary 
due to the fact that previous extraction methods used did not provide good recovery for all 
analytes. A forward Foerster-Mason alkaline extraction was used first in experiment validation 
exploration. While this method facilitated extraction of the four synthetic cannabinoids 
monitored in the project with good recovery, in our extraction, when analyzing post-mortem 
samples provided by the OCME laboratory that were a year or older suffered greatly on recovery 
due to intrinsic extraction process. We feel this is due to poor specimen quality and an extraction 
solvent not conducible for all compounds. 
 A different extraction technique was selected for use in the present study after the 
publication of a recent article by Shanks et al. (2014).  They used a sodium carbonate buffer and 
98:2 hexane: ethyl acetate as the organic phase, while also using post-mortem whole blood in 
their experimental work. Since the compounds they studied are similar to AB-Fubinaca and 
ADB-Pinaca, it was hoped that this method would also work for the project analytes of interest. 
When analyzing for matrix effects in the validation process, it was found that only UR-144 
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suffered slightly from matrix effects, so the hexane: ethyl acetate ratio was changed to 80:20 to 
accommodate polarity differences.  Using a hexane and ethyl acetate organic solvent involves a 
non-polar and polar organic phase. The established 80:20 ratio created a solvent that solves 
polarity differences between the four compounds at different ratios. All recovery data was shown 
to be highly effective for all four compounds monitored. This demonstrates the efficacy of the 
new optimized extraction method as well as its efficiency.  
 Specificity testing, also known as interference, was conducted by taking multiple analytes 
through the optimized extraction process to see if any interferences caused problems in the 
ability to detect, identify, or quantitate a targeted analyte. This specificity testing was done by 
spiking whole blood samples with a selected series of twenty alkaline drugs and nine acidic 
neutral drugs (Table 3), as well as 15 other synthetic cannabinoid compounds including: JWH-
250, JWH-200; HU-211, (±)-CP 47,497, (±)-CP 47,497 C8 homologue, JWH-019, JWH-122, 
JWH-081, AM-2201, RCS-4, RCS-8, JWH-015, JWH-203, JWH-210, and AM2233.  No 
interferences were detected for any of the tested drugs with the ion monitoring modes used with 
the LC-MS/MS method.  
 Ionization suppression or enhancement studies were applicable to the method used for the 
research effort since the technique utilized specific ionization technology typically used in LC-
MS/MS analyses. These effects were studied by contrasting pre- and post-extraction recoveries 
for the three ions monitored in the experimental method. Pre- and post-extraction recoveries 
were compared to a “neat” vial. The “neat” vial was an un-extracted pure sample containing no 
blood matrix, only 5.0 ng/mL of QC and 5.0 ng/mL of internal standards, evaporated to dryness, 
then reconstituted. From this comparison, matrix percentage, recovery percentage and efficiency 
percentage were calculated. All drug matrix, recovery, and efficiency percentages were within 
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OCME required limits as required for validation data except UR-144. The matrix percentage was 
extremely low, which therefore impacted the recovery percentage. While it is unknown why UR-
144 suffered from matrix effects more greatly than the other analytes of interest, it should be 
explored further for method validation purposes.  
Limit of detection (LOD) as well as the limit of quantitation (LOQ) was assessed after 
establishing the calibration model. The LOD is the lowest concentration of an analyte that can be 
differentiated from a blank matrix, whereas the LOQ is the lowest concentration that can be 
measured within an acceptable bias and precision. The calibration model used was a1/x weighted 
linear calibration, with concentrations ranging from 0.1 to 10 ng/mL.  A low concentration range 
calibration curve was used instead of the commonly used drugs of abuse curves reported at 
micrograms per milliliter; further reasoning being that often synthetic cannabinoids are 
quantitated in blood specimens at low quantitated amounts such as 1 ng/mL or less. Showing 
degradation at lower level limits (0.1-10 ng/mL) is more sensitive and applicable to current 
forensic casework. With the established limit of quantitation being 0.1 ng/mL, a lower limit was 
explored for the limit of detection. It was found that the limit of detection was 0.025 ng/mL, 
meeting the criteria that at least one parent ion and one daughter or qualifier ion integrated 
properly, as well as having a signal to noise ratio of 3:1. The LOD and LOQ criteria are set by 
SWGTOX and required at the OCME Laboratory. 
Linearity is based upon the calibration model established at the research project initiation. 
This model requires at least six different non-zero concentrations to establish the model, and also 
requires a minimum of five replicates per concentration. Linearity was calculated based on the 
equation of the line and requires an R2 value greater than 0.900. Linearity was greater than 0.999 
for all of the quantitated analyte compounds of interest. 
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Precision is defined as the measure of closeness of agreement between a series of 
measurements obtained from multiple samplings of the same homogenous sample.  There are 
two differing precision calculations, those that are within-run and between-run. Within-run 
precision is calculated for each concentration separately for each of the five runs using each 
triplicate used. Between-run is calculated from the combined data from all replicates of each 
concentration level. It is required that the coefficients of variation for all precision data be lower 
than 10%. All compounds of interest met the coefficient of variation validation criteria, having a 
% CV less than 10%.  
Bias studies must be carried out for all quantitative models, as required by SWGTOX. 
These are usually partnered along with precision, contrasting the levels of control with their 
respective expected concentration. Bias validation requires a coefficient of variation less than 
20%. For AB-Fubinaca, XLR-11, and UR-144 this criteria was sufficiently met; however, AB-
Pinaca suffered from bias differences despite meeting precision criteria. The bias percentages for 
the two levels of control were greater than the required <20%. This is currently an unexplained 
phenomenon and will need to be investigated further for future studies involving AB-Pinaca. 
 For the stability portion of the study, at initial 5 ng/mL fortified concentrations, the 
ambient temperature condition proved to be the most variable for all compounds, with XLR-11 
suffering from the most stability fluctuations and degradative losses. Other compounds were 
stable at ambient and refrigerated conditions, while XLR-11 suffered from first-order 
degradation. The frozen storage condition was the most stable condition overall, with all analytes 
proving to be stable at their initial fortified 5 ng/mL concentration. Frozen storage conditions, for 
blood in specific, would be encouraged for all synthetic cannabinoid compounds for ultimate 
stability.  
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AB-Fubinaca was relatively stable throughout the entire study. Suffering from only slight 
degradative losses, frozen conditions remained the most stable throughout the twelve week 
period. Ambient and refrigerated conditions experienced an approximate 7% decrease or 
fluctuation in concentration, while frozen samples experienced a 5% loss overall. This is a small 
percentage, but does demonstrate that samples of this synthetic cannabinoid preserve well at 
ambient and refrigerated conditions, and best overall at frozen conditions.  
While being structurally similar to AB-Fubinaca, AB-Pinaca remained even more stable 
under all storage conditions. Throughout the first six week period, after which this analyte 
dropped below the acceptable bias parameter, AB-Pinaca only suffered less than 5% of 
degradative loss. Being the most stable in frozen conditions, AB-Pinaca was very stable in all 
temperature conditions throughout the entire study while also having the smallest replicate 
coefficient of variation. This demonstrates that AB-Pinaca is extremely stable in biological 
specimens, especially blood, for twelve weeks and in multiple storage conditions. 
UR-144 remained relatively stable throughout the twelve weeks of testing. Overall, the 
UR-144 compound had very small percentages of degradative loss throughout the study, but 
suffered from the most concentration fluctuation over time. While stability remained around the 
initial established 4.2 ng value, UR-144 showed changes in concentration over the time period, 
which is reflected in the coefficients of variation calculated for each analysis time point. 
However, the stability of UR-144 remained constant throughout the entirety of the study, 
favoring the storage conditions of refrigerated or frozen temperatures. No significant degradative 
losses were encountered in UR-144 concentrations for the three storage conditions, and 
fluctuations in concentration could be contributed to the matrix effects encountered in the 
validation portion of study.  
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Fluctuations in overall concentration can be observed for all of the studied compounds. 
However, these fluctuations are parallel for each compound, suggesting the effects that human 
handling variability adds to the procedure. Human error, pipetting discrepancies, etc. can all add 
to variability for the overall concentration of the analyte. However, these fluctuations were not 
detrimental to the experiment as a whole or statistically significant in magnitude. 
XLR-11 was the most unstable compound under ambient and refrigerated temperature 
conditions. While Kacinko (2011) showed that four independent JWH compounds were 
relatively stable for 30 days under ambient conditions, XLR-11 suffered approximately 73% 
degradative loss in the first three weeks of analysis in the ambient temperature conditions, 
demonstrating that not all synthetic cannabinoid compounds are relatable. Further so, 32% of the 
initial compound was lost under refrigerated conditions during the first three- week period. 
Therefore, it cannot be easily concluded that all synthetic cannabinoid compounds are relatively 
stable for thirty days. Even further, after a six week period, XLR-11 suffered dropout at ambient 
and refrigerated conditions of 90% and 51%, respectively. At the final twelve week time point, 
nearly 97% of the initial ambient XLR-11 was lost, 71% being lost in the refrigerated sample. 
Frozen conditions proved to be the only way for storage of biological specimens containing 
XLR-11 for optimal preservation. Frozen conditions suffered less than 5% of degradative losses. 
From the data plots, it is observed that XLR-11 follows first-order pharmacokinetic degradation. 
First-order reactions proceed at a rate that depends on the concentration of one reactant. These 
reactions follow exponential decay, which was expressed by XLR-11. The results of this study 
suggest that any specimens possibly containing XLR-11 should be frozen upon receipt, since 
refrigerated conditions resulted in significant losses.  
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The calculated values for XLR-11 half-life and time until LOQ reached are very useful to 
determine the shelf-life of XLR-11 at different temperature conditions, as well as determining 
approximately how long until the bottom of the concentration level is reached before dropping 
beneath the quantitation limit. The half-life of XLR-11 in ambient conditions was determined to 
be approximately 17 days. This is the time until half of the initial concentration has been lost. 
This is an unusually short amount of time to process forensic casework before the possible 
evidentiary concentration is affected significantly. The time until the LOQ was reached was 
calculated to be 85 days, just one day after the completion of the stability timeline.  Evidence 
samples stored under ambient conditions must be processed in a timely manner upon receipt so 
that concentrations are not detrimentally affected. Samples stored under refrigerated conditions 
fared better when compared to ambient conditions, but significant loss could still be encountered 
since the estimated half-life under refrigerated conditions is 27 days. It would take 250 days for 
XLR-11 to reach the LOQ, which is significantly longer than ambient conditions; however, it 
would still be recommended for biological samples containing XLR-11 to be stored under frozen 
conditions. 
The stability of XLR-11 compared to UR-144 was originally hypothesized to be 
relatively comparable due to their structural similarities; however, this was not the case. While 
UR-144 proved to be stable under multiple storage conditions, XLR-11 suffered significant 
compound degradation. While these two compounds are somewhat structurally similar, both 
containing the tetramethylcyclopropyl group, XLR-11 exists as the halogenated form of UR-144, 
adding the 5-fluoropentyl chain to the aminoalkylindole backbone. No current published data to 
support whether the addition of the fluoropentyl chain would influence stability is known to this 
study.  
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An interesting trend may have been observed in this study in the area of halogenated 
compounds versus non-halogenated compounds. AB-Fubinaca and AB-Pinaca both exist with 
the same similar indazole backbone, but differ with the addition of contrasting functional groups. 
AB-Fubinaca includes the addition of the fluorobenzene moiety, whereas AB-Pinaca includes the 
carboxamide moiety. While AB-Fubinaca did not suffer from large stability effects, it did 
degrade more than AB-Pinaca. These degradative effects were not statistically significant or 
detrimental to the overall compound stability, but it is something that could be investigated 
further. This is especially true for contrasting XLR-11 and UR-144, which also involves the 
comparison of halogenated and non-halogenated compounds. XLR-11 clearly suffered from 
degradation, while UR-144 remained stable. As previously mentioned, XLR-11 is a halogenated 
compound containing the 5-fluoropentyl chain whereas UR-144 contains no halogen in this 
position. Considering these two compounds are so closely related also, it is intriguing to know 
whether the halogenation alters the stability of these compounds in blood, or if another 
interference or effect is contributing to the stability losses and effects of XLR-11.  
Summarizing, AB-Pinaca, AB-Fubinaca, and UR-144 remain fairly stable in whole blood 
for extended amounts of time regardless of storage condition. XLR-11 is extremely sensitive to 
temperature conditions and degradative effects and must therefore be stored in appropriate 
conditions for optimal preservation. All compounds suffered from increased fluctuations at 
ambient temperatures, which is why it should be suggested that biological samples suspected of 
containing synthetic cannabinoids be stored, at least, in refrigerated or preferably in frozen 
conditions. Frozen conditions preserved XLR-11 and kept this compound stable from 
degradation. The underlying issue addressed in this study is that the stability of the synthetic 
cannabinoids studied can be time sensitive. Forensic testing and analysis should be done in a 
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timely manner, due to the fact that XLR-11 is extremely sensitive to degradative losses and can 
be lost completely from evidentiary samples if not handled properly. 
Limitations 
 When evaluating the results of this project, there are several things to keep in mind that 
influence the research and its interpretation. Firstly, the parameters of the project included only 
four synthetic cannabinoid compounds, when in actuality there are hundreds that have been 
discovered. Unpublished data from the OCME and OSBI laboratories indicate that these four 
compounds are the most recently encountered in forensic casework and were therefore selected 
as the most relevant to be studied. The stability of other synthetic cannabinoids is largely 
unknown, aside from those mentioned over the course of this narrative. 
 Another limitation of this study is that the monitoring period was 12 weeks. This time 
period was longer than other previously published stability studies associated with synthetic 
cannabinoids; however, stability beyond twelve weeks was not monitored. Due to the relevance 
of applying the findings to the fields of forensic chemistry and toxicology, case prioritization 
schemes would hopefully be analyzed within the 12 week period monitored in the study. 
According to 2009 statistics provided from the U.S. Department of Justice (2012), publically-
funded forensic crime laboratories in the toxicology section have backlog cases (cases not 
completed after 30 days) of less than 3%. Thus whether significant degradative losses 
subsequently occurred after the testing period was completed is not known. 
 This project also only dealt with the processing and extracting of human blood. Often in 
forensic toxicology or chemistry laboratories, other specimens such as serum or plasma, urine, or 
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tissues are submitted for analysis. This study only validates and details a method for the analysis 
of the four mentioned synthetic cannabinoids in human whole blood. 
Suggestions for Further Research 
 While the synthetic cannabinoid is quickly evolving, it is hoped that soon these drugs will 
no longer be the “trending” synthetic drug market. As with other drugs throughout history, drug 
popularity changes over time. However, the growing market of compounds for synthetic 
cannabinoids cannot be ignored. As new compounds are detected in forensic casework, 
degradation information may be useful in particular for forensic caseload prioritization. With that 
being said, similar studies to this one will undoubtedly need to be conducted related to the new 
compounds.  
 The pursuit of chemical structure differences and how they may or may not influence 
stability could also be suggested. As seen in this study, halogenated compounds suffered from 
more degradation than their non-halogenated related compounds. While there hasn’t been any 
evidence of this in other publications, synthetic cannabinoid stability in biological matrices has 
not been studied in depth. Greater understanding of the field of illicit synthetic drug chemistry 
would be of benefit to forensic science. 
Conclusion 
 This study has demonstrated the analytical issues that can be faced when encountering 
synthetic drugs in the forensic laboratory. An analytical method was developed and validated for 
analyzing synthetic cannabinoid compounds in human whole blood, as well as generating vital 
stability data for the four studied synthetic cannabinoid compounds. The validation phase of the 
project was necessary not only for method development, but also for OCME usage to establish a 
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working method for analysis of these synthetic cannabinoids. Validation also demonstrates the 
efficiency and accuracy of the method for the three validated compounds, AB-Fubinaca, XLR-
11, and UR-144. The validation criteria for AB-Pinaca were all met with the exception of bias; 
however, any further exploration into this issue was beyond the scope of this project. Stability 
projects are vital for forensic chemists and toxicologists for understanding analyte stability in 
different variable conditions. Due to the lack of stability data published for synthetic 
cannabinoids, the information generated will be useful for those analyzing these compounds. We 
found that out of the four synthetic cannabinoid compounds studied, AB-Fubinaca, AB-Pinaca, 
and UR-144 demonstrated good stability in all temperature conditions. XLR-11 was found to 
have accelerated degradation in ambient conditions and refrigerated conditions, suffering from 
97% loss and 71% loss respectively for each condition.  By demonstrating the relatively rapid 
degradation of XLR-11, analysis for synthetic cannabinoids can be time sensitive. Due to storage 
temperature conditions and molecular differences in structure, significant degradation can be 
encountered when analyzing for synthetic cannabinoids in biological samples. Because of the 
prevalence of these drugs in the synthetic drug market and across the globe, this information will 
be imperative to those in the laboratory analyzing for these compounds and also for law 
enforcement handling possible biological evidence samples. It is clear that biological samples 
containing synthetic cannabinoids should be refrigerated, if not frozen, upon receipt and 
analyzed quickly to prevent any possible degradative losses and to ultimately preserve the 
evidentiary integrity of that specimen. 
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0.5ng 5.0 ng 0.5ng 5.0 ng 0.5ng 5.0 ng 0.5ng 5.0 ng 0.5ng 5.0 ng 0.5ng 5.0 ng
AB-Fubinaca 0.40 4.58 0.42 4.56 0.45 4.79 0.44 5.22 0.44 4.69 0.42 4.54
0.45 4.40 0.44 4.44 0.46 4.52 0.43 4.91 0.39 4.65 0.47 4.39
0.40 4.22 0.38 4.62 0.47 4.70 0.43 4.88 0.40 4.20 0.40 4.31
AB-Pinaca 0.41 3.94 0.38 3.88 0.38 4.07 0.37 4.16 0.36 3.96 0.37 3.61
0.36 3.85 0.35 3.78 0.38 3.93 0.39 3.85 0.35 3.98 0.37 3.64
0.37 3.62 0.38 3.77 0.39 3.91 0.37 3.97 0.34 3.67 0.36 3.46
UR-144 0.45 4.73 0.44 4.87 0.44 5.23 0.45 5.16 0.42 6.30 0.44 4.51
0.46 4.67 0.45 4.80 0.46 5.39 0.45 5.08 0.52 6.44 0.47 4.68
0.46 4.79 0.47 4.70 0.45 5.17 0.48 5.12 0.52 6.32 0.45 4.44
XLR-11 0.46 4.39 0.41 4.43 0.44 4.73 0.44 4.87 0.42 4.28 0.43 4.42
0.43 4.39 0.45 4.56 0.44 4.78 0.43 4.73 0.44 4.46 0.44 4.42
0.42 4.24 0.43 4.47 0.46 4.65 0.44 4.66 0.43 4.23 0.45 4.17
8/22/2014 8/26/2014 8/29/2014 9/2/2014 9/9/2014 9/16/2014
STATISTICS
Average 0.42 4.40 0.41 4.54 0.46 4.67 0.43 5.00 0.41 4.51 0.43 4.41
SD 0.03 0.18 0.03 0.09 0.01 0.14 0.01 0.19 0.03 0.27 0.04 0.12
CV 6.93% 4.09% 7.39% 2.02% 2.17% 2.94% 1.33% 3.76% 6.45% 6.03% 8.39% 2.65%
Average 0.38 3.80 0.37 3.81 0.38 3.97 0.38 3.99 0.35 3.87 0.37 3.57
SD 0.03 0.17 0.02 0.06 0.01 0.09 0.01 0.16 0.01 0.17 0.01 0.10
CV 6.96% 4.34% 4.68% 1.60% 1.51% 2.20% 3.07% 3.91% 2.86% 4.48% 1.57% 2.70%
Average 0.46 4.73 0.45 4.79 0.45 5.26 0.46 5.12 0.49 6.35 0.45 4.54
SD 0.01 0.06 0.02 0.09 0.01 0.11 0.02 0.04 0.06 0.08 0.02 0.12
CV 1.26% 1.27% 3.37% 1.78% 2.22% 2.16% 3.77% 0.78% 11.86% 1.19% 3.37% 2.72%
Average 0.44 4.34 0.43 4.49 0.45 4.72 0.44 4.75 0.43 4.32 0.44 4.34
SD 0.02 0.09 0.02 0.07 0.01 0.07 0.01 0.11 0.01 0.12 0.01 0.14
CV 4.77% 2.00% 4.65% 1.48% 2.59% 1.39% 1.32% 2.25% 2.33% 2.80% 2.27% 3.33%
8/22/2014 8/26/2014 8/29/2014 9/2/2014 9/9/2014 9/16/2014
0.5ng 5.0 ng 0.5ng 5.0 ng 0.5ng 5.0 ng 0.5ng 5.0 ng 0.5ng 5.0 ng 0.5ng 5.0 ng
AB-Fubinaca 0.42 4.70 0.44 4.77 0.40 4.38 0.42 4.84 0.47 4.32 0.47 4.75
0.41 4.61 0.41 4.28 0.42 4.52 0.44 4.59 0.41 4.25 0.47 4.81
0.41 4.47 0.48 4.78 0.39 4.55 0.48 4.33 0.45 4.07 0.41 4.61
AB-Pinaca 0.37 3.75 0.37 3.99 0.34 3.76 0.36 3.87 0.36 3.70 0.36 3.80
0.37 3.62 0.38 3.65 0.31 3.78 0.34 3.91 0.33 3.67 0.36 3.66
0.38 3.53 0.39 3.81 0.34 3.88 0.35 3.67 0.36 3.64 0.38 3.68
UR-144 0.48 5.03 0.44 4.82 0.40 4.94 0.32 4.55 0.30 5.98 0.46 4.77
0.44 4.35 0.45 4.36 0.42 4.52 0.40 4.76 0.40 5.75 0.48 5.12
0.46 4.53 0.45 5.27 0.43 4.65 0.40 4.38 0.44 5.19 0.47 4.73
XLR-11 0.42 4.69 0.44 4.50 0.38 4.38 0.42 4.47 0.44 4.30 0.43 4.59
0.44 4.33 0.45 4.33 0.42 4.54 0.41 4.49 0.40 4.45 0.43 4.52
0.42 4.08 0.44 4.52 0.44 4.39 0.39 4.25 0.41 4.30 0.44 4.42
9/23/2014 11/18/20149/30/2014 10/8/2014 10/21/2014 11/4/2014






Appendix B- Baseline QC Stability Data 
                       
STATISTICS
Average 0.41 4.59 0.44 4.61 0.40 4.48 0.45 4.59 0.44 4.21 0.45 4.72
SD 0.01 0.12 0.04 0.29 0.02 0.09 0.03 0.26 0.03 0.13 0.03 0.10
CV 1.40% 2.52% 7.92% 6.20% 3.79% 2.02% 6.84% 5.56% 6.89% 3.06% 7.70% 2.17%
Average 0.37 3.63 0.38 3.82 0.33 3.81 0.35 3.82 0.35 3.67 0.37 3.71
SD 0.01 0.11 0.01 0.17 0.02 0.06 0.01 0.13 0.02 0.03 0.01 0.08
CV 1.55% 3.04% 2.63% 4.46% 5.25% 1.69% 2.86% 3.37% 4.95% 0.82% 3.15% 2.04%
Average 0.46 4.64 0.45 4.82 0.42 4.70 0.37 4.56 0.38 5.64 0.47 4.87
SD 0.02 0.35 0.01 0.46 0.02 0.22 0.05 0.19 0.07 0.41 0.01 0.21
CV 4.35% 7.60% 1.29% 9.45% 3.67% 4.57% 12.37% 4.17% 18.98% 7.20% 2.13% 4.40%
Average 0.43 4.37 0.44 4.45 0.41 4.44 0.41 4.40 0.42 4.35 0.43 4.51
SD 0.01 0.31 0.01 0.10 0.03 0.09 0.02 0.13 0.02 0.09 0.01 0.09
CV 2.71% 7.02% 1.30% 2.35% 7.39% 2.02% 3.76% 3.02% 5.00% 1.99% 1.33% 1.89%
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Appendix C- Within Run QC Validation Data 
AB-Fubinaca 
 



































% CV 6.84% 5.56%
 Highest % CV 8.4% 6.2%
% CV Limit <10 % <10 %








































% CV 2.86% 3.37%
 Highest % CV 5.2% 4.5%
% CV Limit <10 % <10 %








































% CV 12.37% 4.17%
 Highest % CV 12.4% 9.4%
% CV Limit <10 % <10 %








































% CV 3.76% 3.02%
 Highest % CV 7.4% 7.0%
% CV Limit <10 % <10 %
STABILITY OF SYNTHETIC CANNABINOIDS  77 
 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































STABILITY OF SYNTHETIC CANNABINOIDS  78 
 
Appendix D Continued 
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